<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T09:09:32Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:9017949" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:9017949</identifier>
        <datestamp>2022-04-20</datestamp>
        <setSpec>plosmed</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">PLoS Med</journal-id>
              <journal-id journal-id-type="iso-abbrev">PLoS Med</journal-id>
              <journal-id journal-id-type="publisher-id">plos</journal-id>
              <journal-title-group>
                <journal-title>PLoS Medicine</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1549-1277</issn>
              <issn pub-type="epub">1549-1676</issn>
              <publisher>
                <publisher-name>Public Library of Science</publisher-name>
                <publisher-loc>San Francisco, CA USA</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC9017949</article-id>
              <article-id pub-id-type="pmcid">PMC9017949</article-id>
              <article-id pub-id-type="pmc-uid">9017949</article-id>
              <article-id pub-id-type="pmid">35439246</article-id>
              <article-id pub-id-type="doi">10.1371/journal.pmed.1003966</article-id>
              <article-id pub-id-type="publisher-id">PMEDICINE-D-21-04741</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Research Article</subject>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Medical Conditions</subject>
                    <subj-group>
                      <subject>Cerebrovascular Diseases</subject>
                      <subj-group>
                        <subject>Stroke</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Neurology</subject>
                    <subj-group>
                      <subject>Cerebrovascular Diseases</subject>
                      <subj-group>
                        <subject>Stroke</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Vascular Medicine</subject>
                    <subj-group>
                      <subject>Stroke</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Public and Occupational Health</subject>
                    <subj-group>
                      <subject>Behavioral and Social Aspects of Health</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Nutrition</subject>
                    <subj-group>
                      <subject>Diet</subject>
                      <subj-group>
                        <subject>Alcohol Consumption</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Nutrition</subject>
                    <subj-group>
                      <subject>Diet</subject>
                      <subj-group>
                        <subject>Alcohol Consumption</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Computer and Information Sciences</subject>
                  <subj-group>
                    <subject>Computer Networks</subject>
                    <subj-group>
                      <subject>Internet</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Epidemiology</subject>
                    <subj-group>
                      <subject>Medical Risk Factors</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Nutrition</subject>
                    <subj-group>
                      <subject>Diet</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Nutrition</subject>
                    <subj-group>
                      <subject>Diet</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Public and Occupational Health</subject>
                    <subj-group>
                      <subject>Physical Activity</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Medical Conditions</subject>
                    <subj-group>
                      <subject>Cerebrovascular Diseases</subject>
                      <subj-group>
                        <subject>Stroke</subject>
                        <subj-group>
                          <subject>Ischemic Stroke</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Neurology</subject>
                    <subj-group>
                      <subject>Cerebrovascular Diseases</subject>
                      <subj-group>
                        <subject>Stroke</subject>
                        <subj-group>
                          <subject>Ischemic Stroke</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Vascular Medicine</subject>
                    <subj-group>
                      <subject>Stroke</subject>
                      <subj-group>
                        <subject>Ischemic Stroke</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Evaluation of an online intervention for improving stroke survivors’ health-related quality of life: A randomised controlled trial</article-title>
                <alt-title alt-title-type="running-head">Prevent 2nd stroke</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5163-3228</contrib-id>
                  <name>
                    <surname>Guillaumier</surname>
                    <given-names>Ashleigh</given-names>
                  </name>
                  <role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
                  <role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
                  <role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
                  <role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role>
                  <role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role>
                  <role content-type="http://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
                  <role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role>
                  <role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role>
                  <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
                  <xref rid="aff001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="aff002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="cor001" ref-type="corresp">*</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Spratt</surname>
                    <given-names>Neil J.</given-names>
                  </name>
                  <role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
                  <role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
                  <role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role>
                  <role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role>
                  <role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role>
                  <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
                  <xref rid="aff001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="aff002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="aff003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8587-0934</contrib-id>
                  <name>
                    <surname>Pollack</surname>
                    <given-names>Michael</given-names>
                  </name>
                  <role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
                  <role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
                  <role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role>
                  <role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role>
                  <role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role>
                  <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
                  <xref rid="aff001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="aff003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3328-7146</contrib-id>
                  <name>
                    <surname>Baker</surname>
                    <given-names>Amanda</given-names>
                  </name>
                  <role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
                  <role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
                  <role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role>
                  <role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role>
                  <role content-type="http://credit.niso.org/contributor-roles/resources/">Resources</role>
                  <role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role>
                  <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
                  <xref rid="aff001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="aff002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8071-8749</contrib-id>
                  <name>
                    <surname>Magin</surname>
                    <given-names>Parker</given-names>
                  </name>
                  <role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
                  <role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
                  <role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role>
                  <role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role>
                  <role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role>
                  <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
                  <xref rid="aff001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7389-2546</contrib-id>
                  <name>
                    <surname>Turner</surname>
                    <given-names>Alyna</given-names>
                  </name>
                  <role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
                  <role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
                  <role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role>
                  <role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role>
                  <role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role>
                  <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
                  <xref rid="aff001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="aff004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6104-1322</contrib-id>
                  <name>
                    <surname>Oldmeadow</surname>
                    <given-names>Christopher</given-names>
                  </name>
                  <role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
                  <role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
                  <role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
                  <role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role>
                  <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
                  <xref rid="aff002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3298-756X</contrib-id>
                  <name>
                    <surname>Collins</surname>
                    <given-names>Clare</given-names>
                  </name>
                  <role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
                  <role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
                  <role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role>
                  <role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role>
                  <role content-type="http://credit.niso.org/contributor-roles/resources/">Resources</role>
                  <role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role>
                  <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
                  <xref rid="aff001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="aff002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Callister</surname>
                    <given-names>Robin</given-names>
                  </name>
                  <role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
                  <role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
                  <role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role>
                  <role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role>
                  <role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role>
                  <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
                  <xref rid="aff001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="aff002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9474-796X</contrib-id>
                  <name>
                    <surname>Levi</surname>
                    <given-names>Chris</given-names>
                  </name>
                  <role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
                  <role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
                  <role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role>
                  <role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role>
                  <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
                  <xref rid="aff001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="aff003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9452-9735</contrib-id>
                  <name>
                    <surname>Searles</surname>
                    <given-names>Andrew</given-names>
                  </name>
                  <role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
                  <role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
                  <role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role>
                  <role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role>
                  <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
                  <xref rid="aff002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5418-3936</contrib-id>
                  <name>
                    <surname>Deeming</surname>
                    <given-names>Simon</given-names>
                  </name>
                  <role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
                  <role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
                  <role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role>
                  <role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role>
                  <role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role>
                  <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
                  <xref rid="aff002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2405-6327</contrib-id>
                  <name>
                    <surname>Clancy</surname>
                    <given-names>Brigid</given-names>
                  </name>
                  <role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
                  <role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role>
                  <role content-type="http://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
                  <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
                  <xref rid="aff001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8505-622X</contrib-id>
                  <name>
                    <surname>Bonevski</surname>
                    <given-names>Billie</given-names>
                  </name>
                  <role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
                  <role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
                  <role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
                  <role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role>
                  <role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role>
                  <role content-type="http://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
                  <role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role>
                  <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
                  <xref rid="aff005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="aff001">
                <label>1</label>
                <addr-line>University of Newcastle, Callaghan, New South Wales, Australia</addr-line>
              </aff>
              <aff id="aff002">
                <label>2</label>
                <addr-line>Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia</addr-line>
              </aff>
              <aff id="aff003">
                <label>3</label>
                <addr-line>Hunter New England Local Health District, New Lambton Heights, New South Wales, Australia</addr-line>
              </aff>
              <aff id="aff004">
                <label>4</label>
                <addr-line>Deakin University, Geelong, Victoria, Australia</addr-line>
              </aff>
              <aff id="aff005">
                <label>5</label>
                <addr-line>Flinders University, Bedford Park, South Australia, Australia</addr-line>
              </aff>
              <contrib-group>
                <contrib contrib-type="editor">
                  <name>
                    <surname>Willey</surname>
                    <given-names>Joshua Z</given-names>
                  </name>
                  <role>Academic Editor</role>
                  <xref rid="edit1" ref-type="aff"/>
                </contrib>
              </contrib-group>
              <aff id="edit1">
                <addr-line>Columbia University, UNITED STATES</addr-line>
              </aff>
              <author-notes>
                <fn fn-type="COI-statement" id="coi001">
                  <p>The authors have declared that no competing interests exist.</p>
                </fn>
                <corresp id="cor001">* E-mail: <email>Ashleigh.Guillaumier@newcastle.edu.au</email></corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>19</day>
                <month>4</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="collection">
                <month>4</month>
                <year>2022</year>
              </pub-date>
              <volume>19</volume>
              <issue>4</issue>
              <elocation-id>e1003966</elocation-id>
              <history>
                <date date-type="received">
                  <day>15</day>
                  <month>11</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted">
                  <day>16</day>
                  <month>3</month>
                  <year>2022</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© 2022 Guillaumier et al</copyright-statement>
                <copyright-year>2022</copyright-year>
                <copyright-holder>Guillaumier et al</copyright-holder>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="pmed.1003966.pdf"/>
              <abstract>
                <sec id="sec001">
                  <title>Background</title>
                  <p>The aim of this trial was to evaluate the effectiveness of an online health behaviour change intervention—Prevent 2nd Stroke (P2S)—at improving health-related quality of life (HRQoL) amongst stroke survivors at 6 months of follow-up.</p>
                </sec>
                <sec id="sec002">
                  <title>Methods and findings</title>
                  <p>A prospective, blinded-endpoint randomised controlled trial, with stroke survivors as the unit of randomisation, was conducted between March 2018 and November 2019. Adult stroke survivors between 6 and 36 months post-stroke with capacity to use the intervention (determined by a score of ≥4 on the Modified Rankin Scale) and who had access and willingness to use the internet were recruited via mail-out invitations from 1 national and 1 regional stroke registry. Participants completed baseline (<italic toggle="yes">n</italic> = 399) and 6-month follow-up (<italic toggle="yes">n</italic> = 356; 89%) outcome assessments via computer-assisted telephone interviewing (CATI). At baseline the sample had an average age of 66 years (SD 12), and 65% were male. Randomisation occurred at the end of the baseline survey; CATI assessors and independent statisticians were blind to group allocation. The intervention group received remote access for a 12-week period to the online-only P2S program (<italic toggle="yes">n</italic> = 199; <italic toggle="yes">n</italic> = 28 lost at follow-up). The control group were emailed and posted a list of internet addresses of generic health websites (<italic toggle="yes">n</italic> = 200; <italic toggle="yes">n</italic> = 15 lost at follow-up). The primary outcome was HRQoL as measured by the EuroQol Visual Analogue Scale (EQ-VAS; self-rated global health); the outcome was assessed for differences between treatment groups at follow-up, adjusting for baseline measures. Secondary outcomes were HRQoL as measured by the EQ-5D (descriptive health state), diet quality, physical activity, alcohol consumption, smoking status, mood, physical functioning, and independent living. All outcomes included the variable ‘stroke event (stroke/transient ischaemic attack/other)’ as a covariate, and analysis was intention-to-treat. At 6 months, median EQ-VAS HRQoL score was significantly higher in the intervention group than the control group (85 vs 80, difference 5, 95% CI 0.79–9.21, <italic toggle="yes">p</italic> = 0.020). The results were robust to the assumption the data were missing at random; however, the results were not robust to the assumption that the difference in HRQoL between those with complete versus missing data was at least 3 points. Significantly higher proportions of people in the intervention group reported no problems with personal care (OR 2.17, 95% CI 1.05–4.48, <italic toggle="yes">p</italic> = 0.0359) and usual activities (OR 1.66, 95% CI 1.06–2.60, <italic toggle="yes">p</italic> = 0.0256) than in the control group. There were no significant differences between groups on all other secondary outcomes. The main limitation of the study is that the sample comprises mostly ‘well’ stroke survivors with limited to no disability.</p>
                </sec>
                <sec id="sec003">
                  <title>Conclusions</title>
                  <p>The P2S online healthy lifestyle program improved stroke survivors’ self-reported global ratings of HRQoL (as measured by EQ-VAS) at 6-month follow-up. Online platforms represent a promising tool to engage and support some stroke survivors.</p>
                </sec>
                <sec id="sec004">
                  <title>Trial registration</title>
                  <p>Australian New Zealand Clinical Trials Registry <ext-link xlink:href="https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=372659&amp;isReview=true" ext-link-type="uri">ACTRN12617001205325</ext-link>.</p>
                </sec>
              </abstract>
              <abstract abstract-type="toc">
                <p>Ashleigh Guillaumier and colleagues evaluate the effectiveness of an online health behaviour change intervention aimed at improving health-related quality of life amongst stroke survivors.</p>
              </abstract>
              <abstract abstract-type="summary">
                <title>Author summary</title>
                <sec id="sec006">
                  <title>Why was this study done?</title>
                  <list list-type="bullet">
                    <list-item>
                      <p>Stroke can lead to serious consequences for those who survive in terms of physical and cognitive disability, psychological problems, and lower social participation, affecting quality of life.</p>
                    </list-item>
                    <list-item>
                      <p>Improving lifestyle and health risk behaviours (including reducing tobacco and alcohol use, increasing physical activity, improving diet quality, and reducing depression and anxiety) has the potential to significantly improve recovery, enhance quality of life and independent living, and lower risk of recurrent stroke.</p>
                    </list-item>
                    <list-item>
                      <p>The prevalence of health risk factors amongst stroke survivors is high. There is a striking lack of information for stroke survivors and their families about effective lifestyle strategies to help them improve recovery and reduce the risk of recurrent stroke.</p>
                    </list-item>
                  </list>
                </sec>
                <sec id="sec007">
                  <title>What did the researchers do and find?</title>
                  <list list-type="bullet">
                    <list-item>
                      <p>We developed an online program (Prevent 2nd Stroke) providing easily accessible, interactive, tailored healthy lifestyle and behaviour change information that encouraged users to set goals and monitor progress across 6 core modules: (1) smoking, (2) alcohol, (3) activity, (4) nutrition, (5) feelings and mood, and (6) blood pressure.</p>
                    </list-item>
                    <list-item>
                      <p>Adult stroke survivors (<italic toggle="yes">n</italic> = 399) participated in a randomised controlled trial. Participants completed a telephone survey and then were randomised to the online Prevent 2nd Stroke program arm (participants received access to the online program and were encouraged to use it over a 12-week period) or a control arm (participants were sent a list of generic health information websites). All participants completed a follow-up survey 6 months after their first survey.</p>
                    </list-item>
                    <list-item>
                      <p>Participants who had access to the online program rated their overall health and well-being 5 points higher on average than participants who received a generic list of health behaviour information websites.</p>
                    </list-item>
                  </list>
                </sec>
                <sec id="sec008">
                  <title>What do these findings mean?</title>
                  <list list-type="bullet">
                    <list-item>
                      <p>Online platforms are a viable and impactful model to address the health information needs and behaviour change challenges of stroke survivors.</p>
                    </list-item>
                    <list-item>
                      <p>Future studies should test program adaptations particularly for those with greater stroke-related disability.</p>
                    </list-item>
                  </list>
                </sec>
              </abstract>
              <funding-group>
                <award-group id="award001">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100000925</institution-id>
                      <institution>National Health and Medical Research Council</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>APP1125429</award-id>
                  <principal-award-recipient>
                    <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8505-622X</contrib-id>
                    <name>
                      <surname>Bonevski</surname>
                      <given-names>Billie</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="award002">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100001030</institution-id>
                      <institution>National Heart Foundation of Australia</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>101303</award-id>
                  <principal-award-recipient>
                    <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5163-3228</contrib-id>
                    <name>
                      <surname>Guillaumier</surname>
                      <given-names>Ashleigh</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="award003">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100000925</institution-id>
                      <institution>National Health and Medical Research Council</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>GNT1110629/100827</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Spratt</surname>
                      <given-names>Neil J.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="award004">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100000925</institution-id>
                      <institution>National Health and Medical Research Council</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>G1200044</award-id>
                  <principal-award-recipient>
                    <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3328-7146</contrib-id>
                    <name>
                      <surname>Baker</surname>
                      <given-names>Amanda</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <funding-statement>This study was funded by a grant from the National Health and Medical Research Council (NHMRC) (APP1125429) awarded to BB, NJS, MP, AB, PM, AT, CO, CC, RC; <ext-link xlink:href="https://www.nhmrc.gov.au/" ext-link-type="uri">https://www.nhmrc.gov.au/</ext-link>. AG is supported by a post-doctoral fellowship from the Heart Foundation, award number 101303, <ext-link xlink:href="https://www.heartfoundation.org.au/" ext-link-type="uri">https://www.heartfoundation.org.au/</ext-link>. NJS was supported by a co-funded Australian NHMRC/National Heart Foundation Career Development/Future Leader Fellowship [GNT1110629/100827]. AB is supported by a NHMRC Research Fellowship (G1200044). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
              </funding-group>
              <counts>
                <fig-count count="1"/>
                <table-count count="5"/>
                <page-count count="17"/>
              </counts>
              <custom-meta-group>
                <custom-meta id="data-availability">
                  <meta-name>Data Availability</meta-name>
                  <meta-value>All data files are available from the University of Newcastle NOVA database available at <ext-link xlink:href="http://hdl.handle.net/1959.13/1431114" ext-link-type="uri">http://hdl.handle.net/1959.13/1431114</ext-link>.</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <title>Data Availability</title>
              <p>All data files are available from the University of Newcastle NOVA database available at <ext-link xlink:href="http://hdl.handle.net/1959.13/1431114" ext-link-type="uri">http://hdl.handle.net/1959.13/1431114</ext-link>.</p>
            </notes>
          </front>
          <body>
            <sec sec-type="intro" id="sec009">
              <title>Introduction</title>
              <p>Recurrent stroke is the major contributor to stroke-related disability and costs [<xref rid="pmed.1003966.ref001" ref-type="bibr">1</xref>]. Stroke recovery and rehabilitation can continue for years post-stroke, meaning it is critical that stroke survivors are provided with and have access to a range of support options and evidence-based information. Supporting healthy recovery and preventing recurrent stroke can reduce disability and costs and improve quality of life. Despite clinical recommendations and evidence of impact, Australian Stroke Foundation audits [<xref rid="pmed.1003966.ref002" ref-type="bibr">2</xref>,<xref rid="pmed.1003966.ref003" ref-type="bibr">3</xref>] have found that 40% of patients do not receive information on stroke, lifestyle management, second prevention, and recovery at the time of rehabilitation discharge. As stroke has such a wide-ranging impact on individuals, health-related quality of life (HRQoL) is an important outcome in understanding and improving survival as well as informing secondary prevention, with stroke survivors as the centre of care.</p>
              <p>On average, HRQoL after stroke is low compared to general population norms for at least 5 years post-stroke [<xref rid="pmed.1003966.ref004" ref-type="bibr">4</xref>]. Even in patients with transient ischaemic attack (TIA) or minor strokes, stroke recurrence is associated with poor HRQoL [<xref rid="pmed.1003966.ref005" ref-type="bibr">5</xref>]. Mood improvement, cognitive stimulation, and healthier behaviours such as physical activity are linked with better HRQoL amongst stroke survivors [<xref rid="pmed.1003966.ref006" ref-type="bibr">6</xref>]. Health risk factors, particularly physical inactivity and obesity, that persist following a stroke may also contribute to compromised functioning and independent living during recovery [<xref rid="pmed.1003966.ref007" ref-type="bibr">7</xref>]. Even survivors who are not physically disabled, or who have ‘mild’ stroke, experience ongoing ‘invisible’ changes such as fatigue, memory problems, anxiety, mood disturbance, and depression [<xref rid="pmed.1003966.ref008" ref-type="bibr">8</xref>]. Depression and anxiety are modifiable affective states associated with increased post-stroke morbidity and mortality [<xref rid="pmed.1003966.ref009" ref-type="bibr">9</xref>], as well as reduced social participation [<xref rid="pmed.1003966.ref006" ref-type="bibr">6</xref>]. Depression has also been associated with poor adherence to treatment and healthy behaviours [<xref rid="pmed.1003966.ref010" ref-type="bibr">10</xref>]. HRQoL has become a key outcome in stroke research, offering a comprehensive and multidimensional assessment of the impact of stroke, recovery, and social, physical, and psychological health from the patient’s perspective.</p>
              <p>A landmark study identified 10 risk factors associated with 90% of the risk of stroke, including smoking, poor diet, physical inactivity, alcohol intake, depression, waist-to-hip ratio, diabetes mellitus, and cardiac causes [<xref rid="pmed.1003966.ref011" ref-type="bibr">11</xref>]. Addressing behavioural and affective risk factors may not only lower the risk of subsequent stroke but may improve recovery from the first stroke and HRQoL. One modelling study suggests that a strategy combining appropriate medication adherence with diet and physical activity could result in a cumulative relative risk reduction for recurrent stroke of up to 80% [<xref rid="pmed.1003966.ref012" ref-type="bibr">12</xref>]. Unfortunately, these modifiable risk factors are rarely addressed effectively after stroke. Australian Stroke Foundation audits show that 28% of stroke patients in acute settings and 35% in rehabilitation settings do not receive risk factor education [<xref rid="pmed.1003966.ref002" ref-type="bibr">2</xref>,<xref rid="pmed.1003966.ref003" ref-type="bibr">3</xref>].</p>
              <p>Providing behavioural intervention, such as brief advice, education and, counselling, to modify patient health risk behaviours is evidence-based best practice [<xref rid="pmed.1003966.ref013" ref-type="bibr">13</xref>]. Cited barriers to delivery of such care include practitioners’ lack of training, confidence, skills, and time to provide counselling and advice [<xref rid="pmed.1003966.ref014" ref-type="bibr">14</xref>]. There is a striking lack of information on effective health behaviour change strategies for stroke survivors for prevention of a second event [<xref rid="pmed.1003966.ref015" ref-type="bibr">15</xref>]. Although promising, evidence from secondary prevention trials [<xref rid="pmed.1003966.ref016" ref-type="bibr">16</xref>] is sparse and based on shared care and nurse-led programs that are reliant on substantial resources and are costly to the health service.</p>
              <p>Online programs are increasingly popular and may reach a higher number of people than face-to-face programs, including people with mobility restrictions. Up to 80% of patients have an interest in supplementing clinician-delivered support with web-delivered information [<xref rid="pmed.1003966.ref017" ref-type="bibr">17</xref>]. Reviews have consistently demonstrated the effectiveness of online interventions both with non-clinical populations for health behaviour change [<xref rid="pmed.1003966.ref018" ref-type="bibr">18</xref>] and with co-morbid populations for reducing pain, disability, depression, and anxiety [<xref rid="pmed.1003966.ref019" ref-type="bibr">19</xref>,<xref rid="pmed.1003966.ref020" ref-type="bibr">20</xref>]. Only 3 small pilot trials of online health programs for stroke survivors have been reported, but they show promising results [<xref rid="pmed.1003966.ref021" ref-type="bibr">21</xref>–<xref rid="pmed.1003966.ref023" ref-type="bibr">23</xref>]. There is a need for well-powered, well-designed trials of the effectiveness of online interventions for improving quality of life and health behaviours for stroke survivors.</p>
              <p>The primary aim was to evaluate the effectiveness of an online health behaviour change intervention—Prevent 2nd Stroke (P2S)—at improving HRQoL amongst stroke survivors at 6 months of follow-up. The development of the P2S program [<xref rid="pmed.1003966.ref024" ref-type="bibr">24</xref>] and acceptability and feasibility piloting [<xref rid="pmed.1003966.ref025" ref-type="bibr">25</xref>] of the program have been reported elsewhere. Secondary aims were to examine the effect of the online P2S program on 4 health behaviours (smoking, alcohol use, fruit and vegetable intake, and moderate physical activity), mental health (depression and anxiety), and self-reported physical functioning and independent living.</p>
            </sec>
            <sec sec-type="materials|methods" id="sec010">
              <title>Methods</title>
              <sec id="sec011">
                <title>Design</title>
                <p>A prospective, blinded-endpoint randomised controlled trial with stroke survivors as the unit of randomisation was conducted between March 2018 and November 2019. We have reported our trial according to the Consolidated Standards of Reporting Trials (CONSORT) guidelines (<xref rid="pmed.1003966.s001" ref-type="supplementary-material">S1 CONSORT Checklist</xref>). The full study protocol has been described in detail [<xref rid="pmed.1003966.ref026" ref-type="bibr">26</xref>]. Briefly, independent computer-assisted telephone interviewing (CATI) assessors conducted baseline surveys with all participants. The research team mailed correspondence to participants alerting them to group allocation and providing 12-week access to the P2S program for those in the intervention group. Six months following the baseline survey, the blinded CATI assessors conducted follow-up telephone surveys. Participants were considered ‘lost to follow-up’ if they were unable to be contacted at the 6-month assessment time point. The study received ethics approval from the University of Newcastle Human Research Ethics Committee (H-2017-0051).</p>
              </sec>
              <sec id="sec012">
                <title>Recruitment</title>
                <p>Participants were recruited through 2 sources: (1) the Australian Stroke Clinical Registry (AuSCR) database and (2) the Hunter Stroke Research Volunteer Register (HSRVR). The AuSCR and HSRVR screened their database registrants against the study eligibility criteria and sent invitation packs on behalf of the study team to potentially eligible individuals. Eligible participants were aged 18 years and over, had been admitted to an AuSCR hospital for acute stroke or TIA (indexed stroke event) or were registered with the HSRVR, were between 6 and 36 months post-stroke, were sufficiently fluent in English, and had sufficient facility in internet use via a home device (e.g., phone, computer, tablet device) or were willing to use public internet services (e.g., public library). The invitation packs contained study consent and consent-to-contact forms. If interested, potential participants sent the completed forms directly to the study team. The study team contacted potential participants via telephone to complete eligibility screening, enrolment, and scheduling of the baseline survey. Participants were ineligible to continue in the trial if they experienced disability at a level that would have limited their capacity to use the intervention (determined by a score of ≥4 on the Modified Rankin Scale) [<xref rid="pmed.1003966.ref027" ref-type="bibr">27</xref>]. The protocol stated an additional exclusion criterion of ‘documented evidence of 2 or more strokes’: This exclusion criterion was removed 2 months into the 12-month recruitment period (and all potential participants who had been excluded on this basis prior to the change were recontacted) to ensure that a sufficient sample size for the trial was obtained.</p>
              </sec>
              <sec id="sec013">
                <title>Randomisation and data collection</title>
                <p>Independent CATI assessors, who were unaware of treatment allocation, completed baseline and follow-up surveys via telephone with all participants. A random number generator embedded in the CATI software was used to allocate participants to the intervention or control group after all baseline questions had been answered. Individuals were randomised at a ratio of 1:1 in permuted blocks of randomly varying size, stratified by state (New South Wales/South Australia, Queensland, Western Australia, Victoria/Tasmania), and type of stroke (stroke, TIA, don’t know).</p>
                <p>To minimise loss to follow-up, participants were asked to provide multiple points of contact (i.e., home phone, mobile, address, email address) and were sent a monthly text message encouraging them to update any out-of-date contact details and providing an approximate date for their 6-month follow-up survey.</p>
              </sec>
              <sec id="sec014">
                <title>Intervention</title>
                <p>Following the baseline survey and randomisation, researchers both emailed and posted letters to notify participants of their group allocation. The intervention period lasted for 12 weeks. During this time all participants received monthly text message reminders to update any outdated contact details; this reminder also provided the approximate date of the follow-up survey. The intervention group received additional fortnightly text message prompts to use the intervention (overlapping P2S program use and contact detail messages were combined, so the intervention group were contacted on a fortnightly basis during the intervention period).</p>
                <sec id="sec015">
                  <title>Intervention group</title>
                  <p>The P2S program was developed using behaviour change theory and co-design principles with stroke survivors, and was pilot tested prior to this trial. The development and testing of the intervention have been described in detail elsewhere [<xref rid="pmed.1003966.ref024" ref-type="bibr">24</xref>,<xref rid="pmed.1003966.ref025" ref-type="bibr">25</xref>]. Briefly, the P2S program is a modularised, tailored program providing evidence-based techniques and information in 6 core modules: (1) blood pressure, (2) smoking, (3) alcohol consumption, (4) physical activity, (5) nutrition, and (6) feelings and mood, as well as a ‘my progress’ section. Each health risk behaviour module commences with 2–3 brief questions regarding the topic of interest (e.g., smoking: smoking status, number of cigarettes per day, interest in quitting) in order to provide tailored information to the user. Users were asked to set specific goals within each module (e.g., physical activity: ‘I will increase physical activity from 0 to 2 sessions, of 10 mins each, per day’) and were provided with information and advice on how to achieve the goal. The advice in each module is tailored to accommodate stroke-related symptoms. Progress against goals was graphed in the ‘my progress’ section to provide feedback to users on their behaviour change.</p>
                </sec>
                <sec id="sec016">
                  <title>Control group</title>
                  <p>Participants in the control group were both posted and emailed a copy of a letter containing links to internet addresses with readily available, generic online health programs and guidelines designed for the general population (e.g., the Australian Department of Health’s How to Quit Smoking website, Australia’s Physical Activity and Sedentary Behaviour Guidelines and Eat for Health websites, the National Health and Medical Research Council’s Australian Guidelines to Reduce Health Risks from Drinking Alcohol, and the Moodgym website).</p>
                </sec>
              </sec>
              <sec id="sec017">
                <title>Outcomes</title>
                <p>The primary outcome was HRQoL at 6-month follow-up measured using the EuroQol Visual Analogue Scale (EQ-VAS). The EQ-VAS forms one part of the EQ-5D-5L instrument measuring HRQoL [<xref rid="pmed.1003966.ref028" ref-type="bibr">28</xref>]. The EQ-VAS records the participant’s self-rated health on a scale from 0 (‘the worst health you can imagine’) to 100 (‘the best health you can imagine’). It is a quantitative measure of health outcome that reflects the participant’s own judgement. The protocol paper lists both EQ-VAS and EQ-5D (i.e., the entire EQ-5D-5L) as dual primary outcomes; however, upon finalising the statistical analysis plan prior to analysis, the independent statisticians advised nominating a sole primary outcome measure. The EQ-VAS was selected as it was used as the basis for the a priori sample size calculations.</p>
                <p>Secondary outcome measures were as follows: additional HRQoL measures using the EQ-5D-5L descriptive system (EQ-5D), which comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) on a 5-level scale from ‘no problems’ to ‘extreme problems’. Physical functioning and independent living were measured using the Barthel Index [<xref rid="pmed.1003966.ref029" ref-type="bibr">29</xref>] and Instrumental Activities of Daily Living (IADL) scales [<xref rid="pmed.1003966.ref030" ref-type="bibr">30</xref>]; depression and anxiety, using the Patient Health Questionnaire–4 item (PHQ-4) [<xref rid="pmed.1003966.ref031" ref-type="bibr">31</xref>]; diet quality, using the Australian Recommended Food Score (ARFS) [<xref rid="pmed.1003966.ref032" ref-type="bibr">32</xref>]; alcohol consumption, using the Alcohol Use Disorders Identification Test–Consumption (AUDIT-C) [<xref rid="pmed.1003966.ref033" ref-type="bibr">33</xref>]; physical activity, using the Godin Leisure-Time Exercise Questionnaire (GLTEQ) [<xref rid="pmed.1003966.ref034" ref-type="bibr">34</xref>]; and smoking status, using self-reported 7-day point prevalence abstinence [<xref rid="pmed.1003966.ref035" ref-type="bibr">35</xref>].</p>
              </sec>
              <sec id="sec018">
                <title>Sample size</title>
                <p>As reported in the protocol, an a priori sample size calculation was conducted. A sample of 160 per treatment arm at follow-up would enable the detection of a 0.25-standard-deviation difference (a 6-point difference) in EQ-VAS (HRQoL) while maintaining a type I error rate of 5% (5% significance threshold) and type II error rate of 20% (80% power). This calculation assumed a correlation between baseline and follow-up HRQoL of 0.6, and a standard deviation of 24 points. Pilot data suggested that 40% of participants recruited at baseline would complete follow-up data [<xref rid="pmed.1003966.ref025" ref-type="bibr">25</xref>]. Thus, a target of 530 consenting participants at baseline was set.</p>
              </sec>
              <sec id="sec019">
                <title>Statistical analysis</title>
                <p>Participant characteristics at baseline were compared descriptively. The outcomes were summarised at baseline and follow-up for intervention and control groups. Means, standard deviations, medians, 25th and 75th percentiles, and minimum and maximum values for continuous variables, and frequencies with percentages of non-missing observations for categorical variables, are provided. Analysis was intention-to-treat.</p>
                <p>The outcomes were assessed for differences between treatment groups at follow up. The outcomes EQ-VAS, AFRS, and EQ-5D were adjusted for baseline measures. For the primary outcome, EQ-VAS, median quantile regression was used to assess the difference between treatment groups. This differs from the linear regression specified in the protocol; however, quantile regression, instead of standard normal regression, was chosen due to the EQ-VAS results violating regression assumptions. Ordinary least squares (OLS) regression showed some skewed and heteroskedasticity residuals. Quantile regression is more robust when OLS regression assumptions are violated.</p>
                <p>The AFRS and EQ-5D index were assessed using standard linear regression. EQ-5D was assessed with heteroskedasticity-consistent standard errors (sandwich or Huber–White) due to the regression not meeting residual variance assumptions. The Barthel Index, IADL, GLTEQ, and PHQ-4 categories were assessed with ordinal logistic regression. AUDIT-C, PHQ-4 anxiety and depression, and EQ-5D sub-items were assessed with logistic regression.</p>
                <p>All outcomes included the randomisation variable ‘stroke event’ as a covariate. The randomisation variable ‘state of residence’ was not included due to low numbers in some states. Linear estimates or odds ratios (ORs) along with 95% confidence intervals and <italic toggle="yes">p</italic>-values are provided where appropriate.</p>
                <p>Differences between consenters and non-consenters of the AuSCR mail-out were assessed with Fisher’s exact tests for categorical variables and <italic toggle="yes">t</italic> tests for continuous variables.</p>
                <p>Missing data were assumed to be missing at random (MAR). Multiple imputation using the chained regression equation method with 50 imputations was used. Model estimates were pooled across imputations using Rubin’s method. The pooled estimates are provided, together with 95% confidence intervals and Wald <italic toggle="yes">p</italic>-values. Sensitivity to the MAR assumption was assessed using a tipping point approach, allowing the data to be missing not at random (MNAR). Assuming patients who failed to complete the follow-up questionnaire were likely to have poorer health, a negative shift parameter was added to EQ-VAS during imputation. The shift parameter corresponds to the expected difference in HRQoL between those with and without missing data. A range of shift parameter values were tested, until EQ-VAS no longer showed a statistically significant effect at a <italic toggle="yes">p</italic>-value of 0.05.</p>
                <p>Statistical analyses were programmed using SAS version 9.4 (SAS Institute, Cary, North Carolina, US).</p>
              </sec>
            </sec>
            <sec sec-type="results" id="sec020">
              <title>Results</title>
              <p>There was a total of 399 consenting participants eligible for randomisation: 199 were randomised to the intervention group, and 200 to the control group. A total of 377 participants were recruited via the AuSCR, while 22 were recruited through the HSRVR. In total, 43 (10.8%) participants were lost to follow-up (including 5 who withdrew) (see <xref rid="pmed.1003966.g001" ref-type="fig">Fig 1</xref>). No relevant safety events were reported over the course of the trial. <xref rid="pmed.1003966.t001" ref-type="table">Table 1</xref> shows the baseline socio-demographic characteristics of the participants, and <xref rid="pmed.1003966.t002" ref-type="table">Table 2</xref> shows the outcome variable descriptive statistics for baseline and follow-up. Overall, participants were largely an able, independent, non-smoking, healthy eating, and active cohort of stroke survivors, with few indications of anxiety or depression at baseline, although they did report consuming alcohol at high levels. The participant characteristics of the groups were well balanced at baseline. The control group had 15/200 (7.5%) lost to follow-up, while the intervention group had 28/199 (14%). The difference in loss to follow-up between groups was low (6.5%), although statistically significant, <italic toggle="yes">p</italic> = 0.034.</p>
              <fig position="float" id="pmed.1003966.g001">
                <object-id pub-id-type="doi">10.1371/journal.pmed.1003966.g001</object-id>
                <label>Fig 1</label>
                <caption>
                  <title>Study CONSORT flow diagram.AuSCR, Australian Stroke Clinical Registry; HSRVR, Hunter Stroke Research Volunteer Register.</title>
                </caption>
                <graphic xlink:href="pmed.1003966.g001" position="float"/>
              </fig>
              <table-wrap position="float" id="pmed.1003966.t001">
                <object-id pub-id-type="doi">10.1371/journal.pmed.1003966.t001</object-id>
                <label>Table 1</label>
                <caption>
                  <title>Demographic characteristics by treatment group at baseline.</title>
                </caption>
                <alternatives>
                  <graphic xlink:href="pmed.1003966.t001" id="pmed.1003966.t001g" position="float"/>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Variable</th>
                        <th align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Statistic/category</th>
                        <th align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Control<break/>(<italic toggle="yes">n</italic> = 200)<xref rid="t001fn002" ref-type="table-fn">*</xref></th>
                        <th align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Intervention<break/>(<italic toggle="yes">n</italic> = 199)<xref rid="t001fn002" ref-type="table-fn">*</xref></th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="3" style="background-color:#FFFFFF" colspan="1">Age</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                          <italic toggle="yes">n</italic>
                        </td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">199</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">199</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">mean (SD), years</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">68 (12)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">67 (12)</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">median (minimum, maximum), years</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">70 (20, 90)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">68 (20, 93)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="2" style="background-color:#FFFFFF" colspan="1">Sex</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Female</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">66 (33%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">73 (37%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Male</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">134 (67%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">126 (63%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="6" style="background-color:#FFFFFF" colspan="1">State</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">New South Wales</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">20 (10%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">21 (11%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Queensland</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">89 (45%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">88 (44%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">South Australia</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">1 (0.5%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">—</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Tasmania</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">9 (4.5%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">12 (6.0%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Victoria</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">79 (40%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">77 (39%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Western Australia</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">2 (1.0%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">1 (0.5%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="3" style="background-color:#FFFFFF" colspan="1">Stroke type</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Don’t know</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">8 (4.0%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">10 (5.0%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Stroke</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">120 (60%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">119 (60%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Transient ischaemic attack</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">72 (36%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">70 (35%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="2" style="background-color:#FFFFFF" colspan="1">Country of birth</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Australia</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">151 (76%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">156 (78%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Other</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">48 (24%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">43 (22%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="2" style="background-color:#FFFFFF" colspan="1">Indigenous status</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Aboriginal and/or Torres Strait Islander</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">2 (1.0%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">1 (0.5%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Neither</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">196 (99%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">196 (99.5%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="4" style="background-color:#FFFFFF" colspan="1">Income</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">≤AU$399 (US$304) per week</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">57 (29%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">52 (26%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">AU$400–AU$999 (US$305–US$762) per week</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">82 (41%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">75 (38%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">≥AU$1,000 (US$763) per week</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">46 (23%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">50 (25%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Don’t know/refused</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">14 (7%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">20 (10%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="3" style="background-color:#FFFFFF" colspan="1">Walk on admission to hospital (time of stroke)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Yes</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">102 (51%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">118 (59%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">No</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">85 (43%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">68 (34%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Unknown</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">13 (6.5%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">13 (6.5%)</td>
                      </tr>
                    </tbody>
                  </table>
                </alternatives>
                <table-wrap-foot>
                  <fn id="t001fn001">
                    <p>Data are given as <italic toggle="yes">n</italic> (percent) unless otherwise indicated.</p>
                  </fn>
                  <fn id="t001fn002">
                    <p>*Not all <italic toggle="yes">n</italic>’s add to 100% due to missing data.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <table-wrap position="float" id="pmed.1003966.t002">
                <object-id pub-id-type="doi">10.1371/journal.pmed.1003966.t002</object-id>
                <label>Table 2</label>
                <caption>
                  <title>Outcome variable descriptive statistics for baseline and follow-up time points.</title>
                </caption>
                <alternatives>
                  <graphic xlink:href="pmed.1003966.t002" id="pmed.1003966.t002g" position="float"/>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th align="left" rowspan="2" style="background-color:#FFFFFF" colspan="1">Variable</th>
                        <th align="left" rowspan="2" style="background-color:#FFFFFF" colspan="1">Statistic/category</th>
                        <th align="left" colspan="2" style="background-color:#FFFFFF" rowspan="1">Baseline</th>
                        <th align="left" colspan="2" style="background-color:#FFFFFF" rowspan="1">Follow-up</th>
                      </tr>
                      <tr>
                        <th align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Control<break/>(<italic toggle="yes">n</italic> = 200)<xref rid="t002fn002" ref-type="table-fn">*</xref></th>
                        <th align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Intervention<break/>(<italic toggle="yes">n</italic> = 199)<xref rid="t002fn002" ref-type="table-fn">*</xref></th>
                        <th align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Control<break/>(<italic toggle="yes">n</italic> = 185)<xref rid="t002fn002" ref-type="table-fn">*</xref></th>
                        <th align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Intervention<break/>(<italic toggle="yes">n</italic> = 171)<xref rid="t002fn002" ref-type="table-fn">*</xref></th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="4" style="background-color:#FFFFFF" colspan="1">EQ-VAS</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                          <italic toggle="yes">n</italic>
                        </td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">199</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">197</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">185</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">171</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">mean (SD)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">77.4 (15.9)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">79.5 (15.0)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">78.1 (17.2)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">80.4 (16.8)</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">median (min, max)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">80 (20, 100)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">80 (20, 100)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">80 (8, 100)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">85.0 (9, 100)</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">median (Q1, Q3)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">80 (70, 90)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">80 (72, 90)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">80 (70, 90)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">85.0 (75, 90)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="4" style="background-color:#FFFFFF" colspan="1">EQ-5D-5L (UK)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                          <italic toggle="yes">n</italic>
                        </td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">198</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">197</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">185</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">171</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">mean (SD)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.82 (0.17)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.83 (0.18)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.82 (0.17)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.85 (0.17)</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">median (min, max)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.84 (0.10, 1.00)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.84 (−0.06, 1.00)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.84 (0.11, 1.00)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.88 (−0.06, 1.00)</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">median (Q1, Q3)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.84 (0.73, 1.00)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.84 (0.74, 1.00)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.84 (0.74, 1.00)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.88 (0.77, 1.00)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="3" style="background-color:#FFFFFF" colspan="1">Barthel Index</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Moderate (61–90)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">13 (6.5%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">11 (5.7%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">20 (11%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">10 (5.9%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Slight (91–99)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">41 (21%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">30 (15%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">23 (13%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">29 (17%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Independent (100)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">145 (73%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">153 (79%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">141 (77%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">130 (77%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="3" style="background-color:#FFFFFF" colspan="1">IADL</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0–6</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">14 (7.0%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">17 (8.6%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">16 (8.6%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">9 (5.3%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">7</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">24 (12%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">15 (7.6%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">18 (9.7%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">20 (12%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">8</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">161 (81%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">165 (84%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">151 (82%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">142 (83%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="4" style="background-color:#FFFFFF" colspan="1">ARFS (max 73)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                          <italic toggle="yes">n</italic>
                        </td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">198</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">197</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">185</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">170</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">mean (SD)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">40.5 (8.8)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">40.1 (9.0)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">40.8 (8.6)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">40.6 (8.1)</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">median (min, max)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">41.5 (17.0, 59.0)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">42.0 (3.0, 58.0)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">42.0 (18.0, 57.0)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">41.0 (19.0, 59.0)</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">median (Q1, Q3)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">41.5 (35.0, 47.0)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">42.0 (34.0, 46.0)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">42.0 (36.0, 47.0)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">41.0 (35.0, 46.0)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="2" style="background-color:#FFFFFF" colspan="1">Smoked in the last 7 days</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">No</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">189 (95%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">191 (97%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">175 (99%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">163 (97%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Yes</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">10 (5.0%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">6 (3.0%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">2 (1.1%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">5 (3.0%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="2" style="background-color:#FFFFFF" colspan="1">Heavy drinking (AUDIT-C)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">No</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">108 (54%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">99 (50%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">100 (54%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">83 (49%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Yes</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">91 (46%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">98 (50%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">85 (46%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">88 (51%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="3" style="background-color:#FFFFFF" colspan="1">GLTEQ</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Sedentary (0–13)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">64 (32%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">52 (26%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">58 (32%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">40 (24%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Moderately active (14–23)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">41 (21%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">60 (30%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">30 (16%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">42 (25%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Active (24+)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">94 (47%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">85 (43%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">95 (52%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">88 (52%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="4" style="background-color:#FFFFFF" colspan="1">PHQ-4</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">None (0–2)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">140 (71%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">146 (74%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">141 (77%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">137 (81%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Mild (3–5)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">36 (18%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">34 (17%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">23 (13%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">22 (13%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Moderate (6–8)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">13 (6.6%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">12 (6.1%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">12 (6.6%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">4 (2.4%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Severe (9–12)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">7 (3.6%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">4 (2.0%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">6 (3.3%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">7 (4.1%)</td>
                      </tr>
                    </tbody>
                  </table>
                </alternatives>
                <table-wrap-foot>
                  <fn id="t002fn001">
                    <p>Data are given as <italic toggle="yes">n</italic> (percent) unless otherwise indicated.</p>
                  </fn>
                  <fn id="t002fn002">
                    <p>*Not all <italic toggle="yes">n</italic>’s add to 100% due to missing data.</p>
                  </fn>
                  <fn id="t002fn003">
                    <p>ARFS, Australian Recommended Food Score; AUDIT-C, Alcohol Use Disorders Identification Test–Consumption; EQ-VAS, EuroQol Visual Analogue Scale; GLTEQ, Godin Leisure-Time Exercise Questionnaire; IADL, Instrumental Activities of Daily Living; max, maximum; min, minimum; OR, odds ratio; PHQ-4, Patient Health Questionnaire–4 item; Q1, first quartile; Q3, third quartile.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <p>Of the participants allocated to the intervention group, 159/199 (80%) accessed and engaged with the online program. The program was designed so that participants could engage with the content as they chose, and overall module access was as follows: nutrition, 120/159 (75%); blood pressure, 119/159 (75%); physical activity, 104/159 (65%); feelings and mood, 100/159 (63%); and alcohol use, 82/159 (52%). Due to a technical error, the back-end metrics for the smoking module were not produced, although the module itself was active and available to the users.</p>
              <p><xref rid="pmed.1003966.t003" ref-type="table">Table 3</xref> summarises the results of the trial for the primary and secondary outcomes. For the primary outcome, the median HRQoL score (EQ-VAS) was higher in the intervention group than the control group at 6-month follow-up (85 versus 80; difference = 5, 95% CI 0.79–9.21, <italic toggle="yes">p</italic> = 0.020).</p>
              <table-wrap position="float" id="pmed.1003966.t003">
                <object-id pub-id-type="doi">10.1371/journal.pmed.1003966.t003</object-id>
                <label>Table 3</label>
                <caption>
                  <title>Regression analysis results for primary and secondary outcomes: Complete case and imputation results.</title>
                </caption>
                <alternatives>
                  <graphic xlink:href="pmed.1003966.t003" id="pmed.1003966.t003g" position="float"/>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th align="left" rowspan="2" style="background-color:#FFFFFF" colspan="1">Model outcome</th>
                        <th align="left" rowspan="2" style="background-color:#FFFFFF" colspan="1">Estimate type</th>
                        <th align="left" colspan="5" style="background-color:#FFFFFF" rowspan="1">Complete case analysis</th>
                        <th align="left" colspan="2" style="background-color:#FFFFFF" rowspan="1">Imputed analysis (<italic toggle="yes">n</italic> = 50)</th>
                      </tr>
                      <tr>
                        <th align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                          <italic toggle="yes">N</italic>
                        </th>
                        <th align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Control group: <italic toggle="yes">N</italic> (%) with characteristic</th>
                        <th align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Intervention group: <italic toggle="yes">N</italic> (%) with characteristic</th>
                        <th align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Estimate (95% CI)</th>
                        <th align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value</th>
                        <th align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Estimate (95% CI)</th>
                        <th align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Health today (EQ-VAS)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Median difference</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">356</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">5.00 (0.79, 9.21)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.020</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">4.64 (0.12, 9.16)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.044</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Barthel Index</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">OR (ordinal)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">353</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">1.07 (0.65, 1.76)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.786</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">1.07 (0.66, 1.74)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.770</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Heavy drinking (AUDIT-C)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">OR</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">355</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">85 (45.9%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">88 (51.5%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">1.23 (0.81, 1.87)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.323</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">1.29 (0.86, 1.92)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.221</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">PHQ-4</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">OR (ordinal)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">352</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.82 (0.49, 1.36)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.437</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.79 (0.48, 1.30)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.350</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">PHQ-4 (anxiety)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">OR</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">351</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">17 (9.34%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">13 (7.60%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.80 (0.38, 1.68)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.548</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.78 (0.38, 1.61)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.501</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">PHQ-4 (depression)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">OR</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">352</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">22 (11.9%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">17 (10.0%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.82 (0.42, 1.60)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.567</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.80 (0.42, 1.54)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.507</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">IADL</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">OR (ordinal)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">356</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">1.14 (0.66, 1.97)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.641</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">1.10 (0.65, 1.85)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.721</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">GLTEQ</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">OR (ordinal)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">353</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">1.15 (0.77, 1.71)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.497</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">1.13 (0.77, 1.67)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.539</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">ARFS</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Mean difference</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">353</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.16 (−1.36, 1.69)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.834</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.21 (−1.37, 1.79)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.795</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">EQ-5D-5L index (UK)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Mean difference</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">354</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.02 (−0.01, 0.05)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.135</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.02 (−0.01, 0.05)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.107</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">EQ-5D-5L index (Germany)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Mean difference</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">354</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.01 (−0.01, 0.03)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.292</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.01 (−0.01, 0.03)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.233</td>
                      </tr>
                    </tbody>
                  </table>
                </alternatives>
                <table-wrap-foot>
                  <fn id="t003fn001">
                    <p>ARFS, Australian Recommended Food Score; AUDIT-C, Alcohol Use Disorders Identification Test–Consumption; EQ-VAS, EuroQol Visual Analogue Scale; GLTEQ, Godin Leisure-Time Exercise Questionnaire; IADL, Instrumental Activities of Daily Living; OR, odds ratio; PHQ-4, Patient Health Questionnaire–4 item.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <p>The secondary outcome EQ-5D sub-item data at follow-up are presented in <xref rid="pmed.1003966.t004" ref-type="table">Table 4</xref>. The majority (&gt;60%) of participants had no problems on any of the items. <xref rid="pmed.1003966.t005" ref-type="table">Table 5</xref> summarises the results of the effects of the trial on the EQ-5D sub-items. While the change in the odds of no problems appears higher in the intervention group for all 5 items, significantly higher proportions of people in the intervention group reported no problems with personal care (159 [93%] versus 159 [86%]; OR 2.17, 95% CI 1.05–4.48, <italic toggle="yes">p</italic> = 0.0359) and usual activities (122 [71%] versus 111 [60%]; OR 1.66, 95% CI 1.06–2.60, <italic toggle="yes">p</italic> = 0.0256) than in the control group.</p>
              <table-wrap position="float" id="pmed.1003966.t004">
                <object-id pub-id-type="doi">10.1371/journal.pmed.1003966.t004</object-id>
                <label>Table 4</label>
                <caption>
                  <title>EQ-5D sub-item data at follow-up.</title>
                </caption>
                <alternatives>
                  <graphic xlink:href="pmed.1003966.t004" id="pmed.1003966.t004g" position="float"/>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Sub-item</th>
                        <th align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Control<break/>(<italic toggle="yes">n</italic> = 185)</th>
                        <th align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Intervention<break/>(<italic toggle="yes">n</italic> = 171)</th>
                        <th align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Total<break/>(<italic toggle="yes">N</italic> = 356)</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                          <bold>Mobility (walking around)</bold>
                        </td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">No problems</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">113 (61%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">120 (70%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">233 (65%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Slight problems</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">46 (25%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">34 (20%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">80 (22%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Moderate problems</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">26 (14%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">14 (8.2%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">40 (11%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Severe problems</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">3 (1.8%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">3 (0.8%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                          <bold>Personal care (washing/dressing)</bold>
                        </td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">No problems</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">159 (86%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">159 (93%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">318 (89%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Slight problems</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">18 (9.7%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">7 (4.1%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">25 (7.0%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Moderate problems</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">8 (4.3%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">5 (2.9%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">13 (3.7%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                          <bold>Usual activities</bold>
                        </td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">No problems</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">111 (60%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">122 (71%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">233 (65%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Slight problems</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">48 (26%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">33 (19%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">81 (23%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Moderate problems</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">20 (11%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">13 (7.6%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">33 (9.3%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Severe problems</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">6 (3.2%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">1 (0.6%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">7 (2.0%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Unable to do my usual activities</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">2 (1.2%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">2 (0.6%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                          <bold>Pain or discomfort</bold>
                        </td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">None</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">113 (61%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">113 (66%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">226 (63%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Slight</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">43 (23%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">34 (20%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">77 (22%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Moderate</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">23 (12%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">21 (12%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">44 (12%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Severe</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">6 (3.2%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">3 (1.8%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">9 (2.5%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                          <bold>Anxiety or depression</bold>
                        </td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Not anxious or depressed</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">127 (69%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">126 (74%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">253 (71%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Slightly anxious or depressed</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">37 (20%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">31 (18%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">68 (19%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Moderately anxious or depressed</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">17 (9.2%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">11 (6.4%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">28 (7.9%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Severely anxious or depressed</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">3 (1.6%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">3 (0.8%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Extremely anxious or depressed</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">1 (0.5%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">3 (1.8%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">4 (1.1%)</td>
                      </tr>
                    </tbody>
                  </table>
                </alternatives>
                <table-wrap-foot>
                  <fn id="t004fn001">
                    <p>Data are given as <italic toggle="yes">n</italic> (percent).</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <table-wrap position="float" id="pmed.1003966.t005">
                <object-id pub-id-type="doi">10.1371/journal.pmed.1003966.t005</object-id>
                <label>Table 5</label>
                <caption>
                  <title>Logistic regression results for dichotomised (no problems versus some problems) EQ-5D sub-items.</title>
                </caption>
                <alternatives>
                  <graphic xlink:href="pmed.1003966.t005" id="pmed.1003966.t005g" position="float"/>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th align="left" rowspan="2" style="background-color:#FFFFFF" colspan="1">Model outcome</th>
                        <th align="left" colspan="4" style="background-color:#FFFFFF" rowspan="1">Complete case analysis</th>
                        <th align="left" colspan="2" style="background-color:#FFFFFF" rowspan="1">Imputed analysis (<italic toggle="yes">n</italic> = 50)</th>
                      </tr>
                      <tr>
                        <th align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Control group: <italic toggle="yes">N</italic> (%) with no problems</th>
                        <th align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Intervention group: <italic toggle="yes">N</italic> (%) with no problems</th>
                        <th align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Odds ratio (95% CI)</th>
                        <th align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value</th>
                        <th align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Odds ratio (95% CI)</th>
                        <th align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Mobility</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">113 (61.1%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">120 (70.2%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">1.50 (0.96, 2.34)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.0746</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">1.44 (0.93, 2.22)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.101</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Personal care</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">159 (85.9%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">159 (93.0%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">2.17 (1.05, 4.48)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.0359</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">2.08 (1.03, 4.20)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.040</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Usual activities</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">111 (60.0%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">122 (71.3%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">1.66 (1.06, 2.60)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.0256</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">1.60 (1.03, 2.48)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.038</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Pain</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">113 (61.1%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">113 (66.1%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">1.24 (0.80, 1.92)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.3341</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">1.17 (0.76, 1.79)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.477</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Anxiety/depression</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">127 (68.6%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">126 (73.7%)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">1.28 (0.81, 2.03)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.2942</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">1.27 (0.81, 2.00)</td>
                        <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.288</td>
                      </tr>
                    </tbody>
                  </table>
                </alternatives>
                <table-wrap-foot>
                  <fn id="t005fn001">
                    <p>Data are given as <italic toggle="yes">n</italic> (percent).</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <p>There were no significant differences between groups for any of the other secondary outcomes at follow-up. In both the intervention and control groups, almost all participants were non-smokers (163 [97%] versus 175 [99%]), participants on average had an excellent varied and healthy diet (mean [SD] ARFS = 40.6 [8.1] versus 40.8 [8.6]), and around half were sufficiently active (88 [52%] versus 95 [52%]), although around half of the sample in both groups were drinking alcohol at risky levels (88 [51%] versus 85 [46%]). Most participants in both the intervention and control groups reported no symptoms of depression or anxiety (137 [81%] versus 141 [77%]) and had high levels of physical functioning (130 [77%] versus 141 [77%]) and independence (142 [83%] versus 151 [83%]).</p>
              <p>Multiple imputation with the MAR assumption did not significantly change the results, indicating that missing data (including loss to follow-up), when assumed to be MAR, did not affect the outcomes of the trial. Tipping point analysis showed that the difference in HRQoL score between intervention and control would lose statistical significance at a shift parameter of −3. A difference of 3 between those missing and not missing data is not unrealistic, meaning that the results may not be robust to the MAR assumption.</p>
            </sec>
            <sec sec-type="conclusions" id="sec021">
              <title>Discussion</title>
              <p>The results indicate the P2S online healthy lifestyle program improved stroke survivors’ self-reported global rating of HRQoL (as measured by EQ-VAS) at 6-month follow-up. Additionally, more stroke survivors in the intervention group reported having no problems with personal care and usual activities compared to those in the control group (as measured by EQ-5D) at 6-month follow-up. There appeared to be no difference between groups at 6-month follow-up for the 4 health risk behaviours (smoking, diet, alcohol, and physical activity), mental health, or physical functioning and independent living.</p>
              <p>The stroke survivors who participated in this study were largely independent, high functioning, and healthy. At baseline, individuals in the control and intervention groups rated themselves in top health (i.e., approximately 80 on the EQ-VAS) at around the same levels as in a non-stroke general population [<xref rid="pmed.1003966.ref036" ref-type="bibr">36</xref>]. In previous stroke rehabilitation studies, survivors rated their global health on the EQ-VAS on average around 60 [<xref rid="pmed.1003966.ref037" ref-type="bibr">37</xref>]. A ceiling effect appears for the EQ-VAS in healthy populations around 90 points, and there is some indication that minimally important differences in stroke populations on the EQ-VAS scale are around 6–8 points. However, this is based on data obtained during the immediate post-stroke recovery period (i.e., up to 3 months post-stroke, when there is a greater capacity to improve) [<xref rid="pmed.1003966.ref038" ref-type="bibr">38</xref>]. It could be expected that a sample with on average top health at baseline might prove harder to produce a change within, and therefore it is remarkable to see a significant 5-point increase in intervention EQ-VAS ratings. In any case, there is a need to test this style of intervention in a less well population.</p>
              <p>The health risk behaviours assessed in this study indicate that the individuals in the sample were relatively healthy at baseline, which may explain why no changes in these behaviours were seen over the intervention period. In our study, the rate of smoking (4%) was lower than the approximately 14% seen in large stroke patient cohort studies [<xref rid="pmed.1003966.ref011" ref-type="bibr">11</xref>]. Similarly, there was limited scope for diet improvement as the average diet ratings of the sample were in the ‘excellent’ category, indicating a nutritious and varied diet aligning with the Australian Dietary Guidelines [<xref rid="pmed.1003966.ref032" ref-type="bibr">32</xref>]. Regarding physical activity, half the sample were ‘active’ and a further quarter ‘moderately active’ at baseline, and this remained stable over the intervention period. The individuals in the study sample overall were more active than the general population [<xref rid="pmed.1003966.ref039" ref-type="bibr">39</xref>]. It may be that diet and exercise were addressed in this sample’s post-stroke rehabilitation care, accounting for such high baseline levels. However, given that post-stroke awareness and knowledge of risk factors such as diet and exercise is typically low [<xref rid="pmed.1003966.ref040" ref-type="bibr">40</xref>], these findings may also suggest a study population selection bias.</p>
              <p>The exception to the largely healthy behaviours reported at baseline among participants was alcohol use. Alcohol use is emerging as a complex area for stroke research. The Mediterranean diet, which allows for moderate daily alcohol consumption, shows a protective cardiovascular effect [<xref rid="pmed.1003966.ref041" ref-type="bibr">41</xref>]. While mild-to-moderate alcohol consumption may have a protective cardiovascular effect, this research is not without criticism [<xref rid="pmed.1003966.ref042" ref-type="bibr">42</xref>]: Such consumption may present other cancer-related health risks, and hazardous or harmful alcohol consumption does remain a clear risk factor for stroke and stroke recurrence. Future interventions might embed alcohol within diet/nutrition content to ensure brief interventions are achieved.</p>
              <p>Rates of anxiety (12%) and depression (12%) at baseline among our relatively ‘well’ stroke survivor sample were much lower than depression (31%) [<xref rid="pmed.1003966.ref043" ref-type="bibr">43</xref>] and anxiety (24%) [<xref rid="pmed.1003966.ref044" ref-type="bibr">44</xref>] rates typically reported in stroke survivors. Compared to the general population, the anxiety rate was similar (14%), although the depression rate among our sample (12%) was double the general population rate (6%) [<xref rid="pmed.1003966.ref045" ref-type="bibr">45</xref>]. There is a clear relationship between depression and stroke [<xref rid="pmed.1003966.ref046" ref-type="bibr">46</xref>], and this can lead to low engagement in protective/preventative health behaviours. The mental health of stroke survivors and its role in prevention of stroke recurrence has been identified as a critical pathway for future research by peak stroke and cardiovascular bodies [<xref rid="pmed.1003966.ref047" ref-type="bibr">47</xref>] and requires further attention. Additionally, given the relationship between post-stroke fatigue and depression, where it is common for the conditions to co-occur or for one to be masked by the other [<xref rid="pmed.1003966.ref048" ref-type="bibr">48</xref>], it is a limitation of the current study that fatigue was not measured; it should be considered critical to assess fatigue in future studies of this nature.</p>
              <p>While the effect of the P2S program is modest overall and may not be robust, an online program can work as a supplementary tool to use at home while still receiving other rehabilitation services. It would be ideal to see a program like P2S offered as part of a toolkit of support options for stroke survivors, and such a program may extend outreach to those who are less well recovered. The Australian Stroke Foundation has developed EnableMe, a similar online platform for resources and information for stroke survivors [<xref rid="pmed.1003966.ref049" ref-type="bibr">49</xref>]. The online format is increasingly being found as an acceptable and effective method to deliver health behaviour information to fill the evidence–practice gap in stroke recovery and support.</p>
              <p>This trial has a number of strengths and limitations. It was a large trial, recruiting from a national cohort of Australian stroke survivors. As described above, generalisability is limited by the sample comprising mostly ‘well’ stroke survivors. However, this trial provides a pathway for future testing and development of the program, with the need for program adaptions to be explored, including in the mode of delivery for those with greater stroke-related disability, such as aphasia, or limited internet access or literacy. The sample recruited for this study were willing and able to use online technology. While this does limit immediate generalisability to the wider stroke population, technology use is growing in older populations. Finally, the response rate at follow-up was lower in the intervention group, which may be a reflection of people who didn’t engage or felt like they did well enough in the online program not completing follow-up. However, there was no difference in groups across most outcomes, so this is unlikely. Supplementary analysis on differences between those who completed the study and those who were lost to follow-up found no differences on any demographic variables (see <xref rid="pmed.1003966.s002" ref-type="supplementary-material">S1 Table</xref>), and the outcome variables were included in the imputation analysis presented in the paper, which would account for any differences between those missing and not missing data in the analysis. Imputation under MAR modelling did not produce any different results; however, the robustness of the MAR assumption is in question. If non-completers had poorer health, the intervention would likely produce a non-significant result.</p>
              <p>The results of the study show that an online program delivering health behaviour change information improved the self-rated HRQoL of stroke survivors at 6-month follow-up. This indicates that prevention and health risk behaviour change care provision through an online platform is an effective model to engage, support, and improve the lives of stroke survivors.</p>
            </sec>
            <sec id="sec022" sec-type="supplementary-material">
              <title>Supporting information</title>
              <supplementary-material id="pmed.1003966.s001" position="float" content-type="local-data">
                <label>S1 CONSORT Checklist</label>
                <caption>
                  <p>(DOCX)</p>
                </caption>
                <media xlink:href="pmed.1003966.s001.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="pmed.1003966.s002" position="float" content-type="local-data">
                <label>S1 Table</label>
                <caption>
                  <title>Demographic comparison of study completers versus those lost to follow-up.</title>
                  <p>(DOCX)</p>
                </caption>
                <media xlink:href="pmed.1003966.s002.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <glossary>
              <title>Abbreviations</title>
              <def-list>
                <def-item>
                  <term>AUDIT-C</term>
                  <def>
                    <p>Alcohol Use Disorders Identification Test–Consumption</p>
                  </def>
                </def-item>
                <def-item>
                  <term>AuSCR</term>
                  <def>
                    <p>Australian Stroke Clinical Registry</p>
                  </def>
                </def-item>
                <def-item>
                  <term>CATI</term>
                  <def>
                    <p>computer-assisted telephone interviewing</p>
                  </def>
                </def-item>
                <def-item>
                  <term>EQ-VAS</term>
                  <def>
                    <p>EuroQol Visual Analogue Scale</p>
                  </def>
                </def-item>
                <def-item>
                  <term>GLTEQ</term>
                  <def>
                    <p>Godin Leisure-Time Exercise Questionnaire</p>
                  </def>
                </def-item>
                <def-item>
                  <term>HRQoL</term>
                  <def>
                    <p>health-related quality of life</p>
                  </def>
                </def-item>
                <def-item>
                  <term>HSRVR</term>
                  <def>
                    <p>Hunter Stroke Research Volunteer Register</p>
                  </def>
                </def-item>
                <def-item>
                  <term>IADL</term>
                  <def>
                    <p>Instrumental Activities of Daily Living</p>
                  </def>
                </def-item>
                <def-item>
                  <term>MAR</term>
                  <def>
                    <p>missing at random</p>
                  </def>
                </def-item>
                <def-item>
                  <term>OR</term>
                  <def>
                    <p>odds ratio</p>
                  </def>
                </def-item>
                <def-item>
                  <term>P2S</term>
                  <def>
                    <p>Prevent 2nd Stroke</p>
                  </def>
                </def-item>
                <def-item>
                  <term>PHQ-4</term>
                  <def>
                    <p>Patient Health Questionnaire–4 item</p>
                  </def>
                </def-item>
                <def-item>
                  <term>TIA</term>
                  <def>
                    <p>transient ischaemic attack</p>
                  </def>
                </def-item>
              </def-list>
            </glossary>
            <ref-list>
              <title>References</title>
              <ref id="pmed.1003966.ref001">
                <label>1</label>
                <mixed-citation publication-type="journal"><name><surname>Luengo-Fernandez</surname><given-names>R</given-names></name>, <name><surname>Paul</surname><given-names>NL</given-names></name>, <name><surname>Gray</surname><given-names>AM</given-names></name>, <name><surname>Pendlebury</surname><given-names>ST</given-names></name>, <name><surname>Bull</surname><given-names>LM</given-names></name>, <name><surname>Welch</surname><given-names>SJ</given-names></name>, <etal>et al</etal>. <article-title>Population-based study of disability and institutionalization after transient ischemic attack and stroke</article-title>. <source>Stroke</source>. <year>2013</year>;<volume>44</volume>(<issue>10</issue>):<fpage>2854</fpage>–<lpage>61</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1161/STROKEAHA.113.001584</pub-id>
<?supplied-pmid 23920019?><pub-id pub-id-type="pmid">23920019</pub-id></mixed-citation>
              </ref>
              <ref id="pmed.1003966.ref002">
                <label>2</label>
                <mixed-citation publication-type="book"><collab>Stroke Foundation</collab>. <source>National stroke audit—acute services report 2019.</source><publisher-loc>Melbourne</publisher-loc>: <publisher-name>Stroke Foundation</publisher-name>; <year>2019</year>.</mixed-citation>
              </ref>
              <ref id="pmed.1003966.ref003">
                <label>3</label>
                <mixed-citation publication-type="book"><collab>Stroke Foundation</collab>. <source>National stroke audit—rehabilitation services report 2020</source>. <publisher-loc>Melbourne</publisher-loc>: <publisher-name>Stroke Foundation</publisher-name>; <year>2020</year>.</mixed-citation>
              </ref>
              <ref id="pmed.1003966.ref004">
                <label>4</label>
                <mixed-citation publication-type="journal"><name><surname>Luengo-Fernandez</surname><given-names>R</given-names></name>, <name><surname>Gray</surname><given-names>AM</given-names></name>, <name><surname>Bull</surname><given-names>L</given-names></name>, <name><surname>Welch</surname><given-names>S</given-names></name>, <name><surname>Cuthbertson</surname><given-names>F</given-names></name>, <name><surname>Rothwell</surname><given-names>PM</given-names></name>. <article-title>Quality of life after TIA and stroke ten-year results of the Oxford Vascular Study</article-title>. <source>Neurology</source>. <year>2013</year>;<volume>81</volume>(<issue>18</issue>):<fpage>1588</fpage>–<lpage>95</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1212/WNL.0b013e3182a9f45f</pub-id>
<?supplied-pmid 24107865?><pub-id pub-id-type="pmid">24107865</pub-id></mixed-citation>
              </ref>
              <ref id="pmed.1003966.ref005">
                <label>5</label>
                <mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>Y-L</given-names></name>, <name><surname>Pan</surname><given-names>Y-S</given-names></name>, <name><surname>Zhao</surname><given-names>X-Q</given-names></name>, <name><surname>Wang</surname><given-names>D</given-names></name>, <name><surname>Johnston</surname><given-names>SC</given-names></name>, <name><surname>Liu</surname><given-names>L-P</given-names></name>, <etal>et al</etal>. <article-title>Recurrent stroke was associated with poor quality of life in patients with transient ischemic attack or minor stroke: finding from the CHANCE trial</article-title>. <source>CNS Neurosci Ther</source>. <year>2014</year>;<volume>20</volume>(<issue>12</issue>):<fpage>1029</fpage>–<lpage>35</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/cns.12329</pub-id>
<?supplied-pmid 25307297?><pub-id pub-id-type="pmid">25307297</pub-id></mixed-citation>
              </ref>
              <ref id="pmed.1003966.ref006">
                <label>6</label>
                <mixed-citation publication-type="journal"><name><surname>Skolarus</surname><given-names>LE</given-names></name>, <name><surname>Burke</surname><given-names>JF</given-names></name>, <name><surname>Brown</surname><given-names>DL</given-names></name>, <name><surname>Freedman</surname><given-names>VA</given-names></name>. <article-title>Understanding stroke survivorship</article-title>. <source>Stroke</source>. <year>2014</year>;<volume>45</volume>(<issue>1</issue>):<fpage>224</fpage>–<lpage>30</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1161/STROKEAHA.113.002874</pub-id>
<?supplied-pmid 24281223?><pub-id pub-id-type="pmid">24281223</pub-id></mixed-citation>
              </ref>
              <ref id="pmed.1003966.ref007">
                <label>7</label>
                <mixed-citation publication-type="journal"><name><surname>Britton</surname><given-names>A</given-names></name>, <name><surname>Brunner</surname><given-names>E</given-names></name>, <name><surname>Kivimaki</surname><given-names>M</given-names></name>, <name><surname>Shipley</surname><given-names>MJ</given-names></name>. <article-title>Limitations to functioning and independent living after the onset of coronary heart disease: what is the role of lifestyle factors and obesity?</article-title><source>Eur J Public Health.</source><year>2011</year>;<volume>22</volume>(<issue>6</issue>):<fpage>831</fpage>–<lpage>5</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/eurpub/ckr150</pub-id>
<?supplied-pmid 22037803?><pub-id pub-id-type="pmid">22037803</pub-id></mixed-citation>
              </ref>
              <ref id="pmed.1003966.ref008">
                <label>8</label>
                <mixed-citation publication-type="journal"><name><surname>Blomgren</surname><given-names>C</given-names></name>, <name><surname>Samuelsson</surname><given-names>H</given-names></name>, <name><surname>Blomstrand</surname><given-names>C</given-names></name>, <name><surname>Jern</surname><given-names>C</given-names></name>, <name><surname>Jood</surname><given-names>K</given-names></name>, <name><surname>Claesson</surname><given-names>L</given-names></name>. <article-title>Long-term performance of instrumental activities of daily living in young and middle-aged stroke survivors—impact of cognitive dysfunction, emotional problems and fatigue.</article-title><source>PLoS ONE.</source><year>2019</year>;<volume>14</volume>(<issue>5</issue>):<fpage>e0216822</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pone.0216822</pub-id><?supplied-pmid 31095631?><pub-id pub-id-type="pmid">31095631</pub-id></mixed-citation>
              </ref>
              <ref id="pmed.1003966.ref009">
                <label>9</label>
                <mixed-citation publication-type="journal"><name><surname>Turner</surname><given-names>A</given-names></name>, <name><surname>Hambridge</surname><given-names>J</given-names></name>, <name><surname>White</surname><given-names>J</given-names></name>, <name><surname>Carter</surname><given-names>G</given-names></name>, <name><surname>Clover</surname><given-names>K</given-names></name>, <name><surname>Nelson</surname><given-names>L</given-names></name>, <etal>et al</etal>. <article-title>depression screening in stroke</article-title>. <source>Stroke</source>. <year>2012</year>;<volume>43</volume>(<issue>4</issue>):<fpage>1000</fpage>–<lpage>5</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1161/STROKEAHA.111.643296</pub-id>
<?supplied-pmid 22363064?><pub-id pub-id-type="pmid">22363064</pub-id></mixed-citation>
              </ref>
              <ref id="pmed.1003966.ref010">
                <label>10</label>
                <mixed-citation publication-type="journal"><name><surname>House</surname><given-names>A</given-names></name>, <name><surname>Knapp</surname><given-names>P</given-names></name>, <name><surname>Bamford</surname><given-names>J</given-names></name>, <name><surname>Vail</surname><given-names>A</given-names></name>. <article-title>Mortality at 12 and 24 months after stroke may be associated with depressive symptoms at 1 month</article-title>. <source>Stroke</source>. <year>2001</year>;<volume>32</volume>(<issue>3</issue>):<fpage>696</fpage>–<lpage>701</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1161/01.str.32.3.696</pub-id>
<?supplied-pmid 11239189?><pub-id pub-id-type="pmid">11239189</pub-id></mixed-citation>
              </ref>
              <ref id="pmed.1003966.ref011">
                <label>11</label>
                <mixed-citation publication-type="journal"><name><surname>O’Donnell</surname><given-names>MJ</given-names></name>, <name><surname>Chin</surname><given-names>SL</given-names></name>, <name><surname>Rangarajan</surname><given-names>S</given-names></name>, <name><surname>Xavier</surname><given-names>D</given-names></name>, <name><surname>Liu</surname><given-names>L</given-names></name>, <name><surname>Zhang</surname><given-names>H</given-names></name>, <etal>et al</etal>. <article-title>Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study.</article-title><source>Lancet</source>. <year>2016</year>;<volume>388</volume>(<issue>10046</issue>):<fpage>761</fpage>–<lpage>75</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S0140-6736(16)30506-2</pub-id>
<?supplied-pmid 27431356?><pub-id pub-id-type="pmid">27431356</pub-id></mixed-citation>
              </ref>
              <ref id="pmed.1003966.ref012">
                <label>12</label>
                <mixed-citation publication-type="journal"><name><surname>Hackam</surname><given-names>DG</given-names></name>, <name><surname>Spence</surname><given-names>JD</given-names></name>. <article-title>Combining multiple approaches for the secondary prevention of vascular events after stroke</article-title>. <source>Stroke</source>. <year>2007</year>;<volume>38</volume>(<issue>6</issue>):<fpage>1881</fpage>–<lpage>5</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1161/STROKEAHA.106.475525</pub-id>
<?supplied-pmid 17431209?><pub-id pub-id-type="pmid">17431209</pub-id></mixed-citation>
              </ref>
              <ref id="pmed.1003966.ref013">
                <label>13</label>
                <mixed-citation publication-type="book"><collab>Stroke Foundation</collab>. <source>Clinical guidelines for stroke management.</source><publisher-loc>Melbourne</publisher-loc>: <publisher-name>Stroke Foundation</publisher-name>; <year>2020</year>.</mixed-citation>
              </ref>
              <ref id="pmed.1003966.ref014">
                <label>14</label>
                <mixed-citation publication-type="journal"><name><surname>Wolfe</surname><given-names>CDA</given-names></name>, <name><surname>Redfern</surname><given-names>J</given-names></name>, <name><surname>Rudd</surname><given-names>AG</given-names></name>, <name><surname>Grieve</surname><given-names>AP</given-names></name>, <name><surname>Heuschmann</surname><given-names>PU</given-names></name>, <name><surname>McKevitt</surname><given-names>C</given-names></name>. <article-title>Cluster randomized controlled trial of a patient and general practitioner intervention to improve the management of multiple risk factors after stroke</article-title>. <source>Stroke</source>. <year>2010</year>;<volume>41</volume>(<issue>11</issue>):<fpage>2470</fpage>–<lpage>6</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1161/STROKEAHA.110.588046</pub-id>
<?supplied-pmid 20864664?><pub-id pub-id-type="pmid">20864664</pub-id></mixed-citation>
              </ref>
              <ref id="pmed.1003966.ref015">
                <label>15</label>
                <mixed-citation publication-type="journal"><name><surname>Lennon</surname><given-names>OC</given-names></name>, <name><surname>Doody</surname><given-names>C</given-names></name>, <name><surname>Choisdealbh</surname><given-names>CN</given-names></name>, <name><surname>Blake</surname><given-names>C</given-names></name>. <article-title>Barriers to healthy-lifestyle participation in stroke: consumer participation in secondary prevention design</article-title>. <source>Int J Rehabil Res</source>. <year>2013</year>;<volume>36</volume>(<issue>4</issue>):<fpage>354</fpage>–<lpage>61</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1097/MRR.0b013e3283643d48</pub-id>
<?supplied-pmid 23873221?><pub-id pub-id-type="pmid">23873221</pub-id></mixed-citation>
              </ref>
              <ref id="pmed.1003966.ref016">
                <label>16</label>
                <mixed-citation publication-type="journal"><name><surname>Lawrence</surname><given-names>M</given-names></name>, <name><surname>Kerr</surname><given-names>S</given-names></name>, <name><surname>McVey</surname><given-names>C</given-names></name>, <name><surname>Godwin</surname><given-names>J</given-names></name>. <article-title>The effectiveness of secondary prevention lifestyle interventions designed to change lifestyle behavior following stroke: summary of a systematic review</article-title>. <source>Int J Stroke</source>. <year>2012</year>;<volume>7</volume>(<issue>3</issue>):<fpage>243</fpage>–<lpage>7</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/j.1747-4949.2012.00771.x</pub-id>
<?supplied-pmid 22405279?><pub-id pub-id-type="pmid">22405279</pub-id></mixed-citation>
              </ref>
              <ref id="pmed.1003966.ref017">
                <label>17</label>
                <mixed-citation publication-type="journal"><name><surname>Monnier</surname><given-names>J</given-names></name>, <name><surname>Laken</surname><given-names>M</given-names></name>, <name><surname>Carter</surname><given-names>CL</given-names></name>. <article-title>Patient and caregiver interest in internet‐based cancer services</article-title>. <source>Cancer Pract</source>. <year>2002</year>;<volume>10</volume>(<issue>6</issue>):<fpage>305</fpage>–<lpage>10</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1046/j.1523-5394.2002.106005.x</pub-id>
<?supplied-pmid 12406053?><pub-id pub-id-type="pmid">12406053</pub-id></mixed-citation>
              </ref>
              <ref id="pmed.1003966.ref018">
                <label>18</label>
                <mixed-citation publication-type="journal"><name><surname>Van den Berg</surname><given-names>MH</given-names></name>, <name><surname>Schoones</surname><given-names>JW</given-names></name>, <name><surname>Vlieland</surname><given-names>TPV</given-names></name>. <article-title>Internet-based physical activity interventions: a systematic review of the literature</article-title>. <source>J Med Internet Res</source>. <year>2007</year>;<volume>9</volume>(<issue>3</issue>):<fpage>e26</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.2196/jmir.9.3.e26</pub-id><?supplied-pmid 17942388?><pub-id pub-id-type="pmid">17942388</pub-id></mixed-citation>
              </ref>
              <ref id="pmed.1003966.ref019">
                <label>19</label>
                <mixed-citation publication-type="journal"><name><surname>Buhrman</surname><given-names>M</given-names></name>, <name><surname>Syk</surname><given-names>M</given-names></name>, <name><surname>Burvall</surname><given-names>O</given-names></name>, <name><surname>Hartig</surname><given-names>T</given-names></name>, <name><surname>Gordh</surname><given-names>T</given-names></name>, <name><surname>Andersson</surname><given-names>G</given-names></name>. <article-title>Individualized guided internet-delivered cognitive-behavior therapy for chronic pain patients with comorbid depression and anxiety: a randomized controlled trial</article-title>. <source>Clin J Pain</source>. <year>2015</year>;<volume>31</volume>(<issue>6</issue>):<fpage>504</fpage>–<lpage>16</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1097/AJP.0000000000000176</pub-id>
<?supplied-pmid 25380222?><pub-id pub-id-type="pmid">25380222</pub-id></mixed-citation>
              </ref>
              <ref id="pmed.1003966.ref020">
                <label>20</label>
                <mixed-citation publication-type="journal"><name><surname>Eccleston</surname><given-names>C</given-names></name>, <name><surname>Fisher</surname><given-names>E</given-names></name>, <name><surname>Craig</surname><given-names>L</given-names></name>, <name><surname>Duggan</surname><given-names>GB</given-names></name>, <name><surname>Rosser</surname><given-names>BA</given-names></name>, <name><surname>Keogh</surname><given-names>E</given-names></name>. <article-title>Psychological therapies (internet-delivered) for the management of chronic pain in adults.</article-title><source>Cochrane Database Syst Rev</source>. <year>2014</year>;<volume>2014</volume>(<issue>2</issue>):<fpage>CD010152</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/14651858.CD010152.pub2</pub-id><?supplied-pmid 24574082?><pub-id pub-id-type="pmid">24574082</pub-id></mixed-citation>
              </ref>
              <ref id="pmed.1003966.ref021">
                <label>21</label>
                <mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>J-I</given-names></name>, <name><surname>Lee</surname><given-names>S</given-names></name>, <name><surname>Kim</surname><given-names>J-H</given-names></name>. <article-title>Effects of a web-based stroke education program on recurrence prevention behaviors among stroke patients: a pilot study</article-title>. <source>Health Educ Res</source>. <year>2013</year>;<volume>28</volume>(<issue>3</issue>):<fpage>488</fpage>–<lpage>501</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/her/cyt044</pub-id>
<?supplied-pmid 23515115?><pub-id pub-id-type="pmid">23515115</pub-id></mixed-citation>
              </ref>
              <ref id="pmed.1003966.ref022">
                <label>22</label>
                <mixed-citation publication-type="journal"><name><surname>Smith</surname><given-names>GC</given-names></name>, <name><surname>Egbert</surname><given-names>N</given-names></name>, <name><surname>Dellman-Jenkins</surname><given-names>M</given-names></name>, <name><surname>Nanna</surname><given-names>K</given-names></name>, <name><surname>Palmieri</surname><given-names>PA</given-names></name>. <article-title>Reducing depression in stroke survivors and their informal caregivers: a randomized clinical trial of a web-based intervention</article-title>. <source>Rehabil Psychol</source>. <year>2012</year>;<volume>57</volume>(<issue>3</issue>):<fpage>196</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1037/a0029587</pub-id><?supplied-pmid 22946607?><pub-id pub-id-type="pmid">22946607</pub-id></mixed-citation>
              </ref>
              <ref id="pmed.1003966.ref023">
                <label>23</label>
                <mixed-citation publication-type="journal"><name><surname>Sureshkumar</surname><given-names>K</given-names></name>, <name><surname>Murthy</surname><given-names>G</given-names></name>, <name><surname>Natarajan</surname><given-names>S</given-names></name>, <name><surname>Naveen</surname><given-names>C</given-names></name>, <name><surname>Goenka</surname><given-names>S</given-names></name>, <name><surname>Kuper</surname><given-names>H</given-names></name>. <article-title>Evaluation of the feasibility and acceptability of the ‘Care for Stroke’ intervention in India, a smartphone-enabled, carer-supported, educational intervention for management of disability following stroke.</article-title><source>BMJ Open</source>. <year>2016</year>;<volume>6</volume>(<issue>2</issue>):<fpage>e009243</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1136/bmjopen-2015-009243</pub-id><?supplied-pmid 26839011?><pub-id pub-id-type="pmid">26839011</pub-id></mixed-citation>
              </ref>
              <ref id="pmed.1003966.ref024">
                <label>24</label>
                <mixed-citation publication-type="journal"><name><surname>Denham</surname><given-names>AMJ</given-names></name>, <name><surname>Guillaumier</surname><given-names>A</given-names></name>, <name><surname>McCrabb</surname><given-names>S</given-names></name>, <name><surname>Turner</surname><given-names>A</given-names></name>, <name><surname>Baker</surname><given-names>AL</given-names></name>, <name><surname>Spratt</surname><given-names>NJ</given-names></name>, <etal>et al</etal>. <article-title>Development of an online secondary prevention programme for stroke survivors: Prevent 2nd Stroke.</article-title><source>BMJ Innov.</source><year>2019</year>;<volume>5</volume>(<issue>1</issue>):<fpage>35</fpage>–<lpage>42</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1136/bmjinnov-2017-000257</pub-id></mixed-citation>
              </ref>
              <ref id="pmed.1003966.ref025">
                <label>25</label>
                <mixed-citation publication-type="journal"><name><surname>Denham</surname><given-names>AMJ</given-names></name>, <name><surname>Halpin</surname><given-names>S</given-names></name>, <name><surname>Twyman</surname><given-names>L</given-names></name>, <name><surname>Guillaumier</surname><given-names>A</given-names></name>, <name><surname>Bonevski</surname><given-names>B</given-names></name>. <article-title>Prevent 2<sup>nd</sup> Stroke: a pilot study of an online secondary prevention program for stroke survivors</article-title>. <source>Aust N Z J Public Health</source>. <year>2018</year>;<volume>42</volume>(<issue>5</issue>):<fpage>484</fpage>–<lpage>90</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/1753-6405.12794</pub-id>
<?supplied-pmid 29888829?><pub-id pub-id-type="pmid">29888829</pub-id></mixed-citation>
              </ref>
              <ref id="pmed.1003966.ref026">
                <label>26</label>
                <mixed-citation publication-type="journal"><name><surname>Guillaumier</surname><given-names>A</given-names></name>, <name><surname>McCrabb</surname><given-names>S</given-names></name>, <name><surname>Spratt</surname><given-names>NJ</given-names></name>, <name><surname>Pollack</surname><given-names>M</given-names></name>, <name><surname>Baker</surname><given-names>AL</given-names></name>, <name><surname>Magin</surname><given-names>P</given-names></name>, <etal>et al</etal>. <article-title>An online intervention for improving stroke survivors’ health-related quality of life: study protocol for a randomised controlled trial</article-title>. <source>Trials</source>. <year>2019</year>;<volume>20</volume>(<issue>1</issue>):<fpage>491</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s13063-019-3604-0</pub-id><?supplied-pmid 31399140?><pub-id pub-id-type="pmid">31399140</pub-id></mixed-citation>
              </ref>
              <ref id="pmed.1003966.ref027">
                <label>27</label>
                <mixed-citation publication-type="journal"><name><surname>Quinn</surname><given-names>TJ</given-names></name>, <name><surname>Lees</surname><given-names>KR</given-names></name>, <name><surname>Hardemark</surname><given-names>H-G</given-names></name>, <name><surname>Dawson</surname><given-names>J</given-names></name>, <name><surname>Walters</surname><given-names>MR</given-names></name>. <article-title>Initial experience of a digital training resource for modified Rankin scale assessment in clinical trials</article-title>. <source>Stroke</source>. <year>2007</year>;<volume>38</volume>(<issue>8</issue>):<fpage>2257</fpage>–<lpage>61</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1161/STROKEAHA.106.480723</pub-id>
<?supplied-pmid 17600236?><pub-id pub-id-type="pmid">17600236</pub-id></mixed-citation>
              </ref>
              <ref id="pmed.1003966.ref028">
                <label>28</label>
                <mixed-citation publication-type="journal"><collab>EuroQol Group</collab>. <article-title>EuroQol—a new facility for the measurement of health-related quality of life.</article-title><source>Health Policy.</source><year>1990</year>;<volume>16</volume>(<issue>3</issue>):<fpage>199</fpage>–<lpage>208</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/0168-8510(90)90421-9</pub-id>
<?supplied-pmid 10109801?><pub-id pub-id-type="pmid">10109801</pub-id></mixed-citation>
              </ref>
              <ref id="pmed.1003966.ref029">
                <label>29</label>
                <mixed-citation publication-type="journal"><name><surname>Mahoney</surname><given-names>FI</given-names></name>, <name><surname>Barthel</surname><given-names>DW</given-names></name>. <article-title>Functional evaluation: the Barthel Index: a simple index of independence useful in scoring improvement in the rehabilitation of the chronically ill.</article-title><source>Md State Med J</source>. <year>1965</year>;<volume>14</volume>:<fpage>61</fpage>–<lpage>5</lpage>.</mixed-citation>
              </ref>
              <ref id="pmed.1003966.ref030">
                <label>30</label>
                <mixed-citation publication-type="journal"><name><surname>Katz</surname><given-names>S.</given-names></name><article-title>Assessing self‐maintenance: activities of daily living, mobility, and instrumental activities of daily living.</article-title><source>J Am Geriatr Soc</source>. <year>1983</year>;<volume>31</volume>(<issue>12</issue>):<fpage>721</fpage>–<lpage>7</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/j.1532-5415.1983.tb03391.x</pub-id>
<?supplied-pmid 6418786?><pub-id pub-id-type="pmid">6418786</pub-id></mixed-citation>
              </ref>
              <ref id="pmed.1003966.ref031">
                <label>31</label>
                <mixed-citation publication-type="journal"><name><surname>Kroenke</surname><given-names>K</given-names></name>, <name><surname>Spitzer</surname><given-names>RL</given-names></name>, <name><surname>Williams</surname><given-names>JB</given-names></name>, <name><surname>Löwe</surname><given-names>B</given-names></name>. <article-title>An ultra-brief screening scale for anxiety and depression: the PHQ-4.</article-title><source>Psychosomatics</source>. <year>2009</year>;<volume>50</volume>(<issue>6</issue>):<fpage>613</fpage>–<lpage>21</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1176/appi.psy.50.6.613</pub-id>
<?supplied-pmid 19996233?><pub-id pub-id-type="pmid">19996233</pub-id></mixed-citation>
              </ref>
              <ref id="pmed.1003966.ref032">
                <label>32</label>
                <mixed-citation publication-type="journal"><name><surname>Collins</surname><given-names>CE</given-names></name>, <name><surname>Burrows</surname><given-names>TL</given-names></name>, <name><surname>Rollo</surname><given-names>ME</given-names></name>, <name><surname>Boggess</surname><given-names>MM</given-names></name>, <name><surname>Watson</surname><given-names>JF</given-names></name>, <name><surname>Guest</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>The comparative validity and reproducibility of a diet quality index for adults: the Australian Recommended Food Score.</article-title><source>Nutrients</source>. <year>2015</year>;<volume>7</volume>(<issue>2</issue>):<fpage>785</fpage>–<lpage>98</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/nu7020785</pub-id>
<?supplied-pmid 25625814?><pub-id pub-id-type="pmid">25625814</pub-id></mixed-citation>
              </ref>
              <ref id="pmed.1003966.ref033">
                <label>33</label>
                <mixed-citation publication-type="journal"><name><surname>Bush</surname><given-names>K</given-names></name>, <name><surname>Kivlahan</surname><given-names>DR</given-names></name>, <name><surname>McDonell</surname><given-names>MB</given-names></name>, <name><surname>Fihn</surname><given-names>SD</given-names></name>, <name><surname>Bradley</surname><given-names>KA</given-names></name>. <article-title>The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking.</article-title><source>Arch Intern Med</source>. <year>1998</year>;<volume>158</volume>(<issue>16</issue>):<fpage>1789</fpage>–<lpage>95</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1001/archinte.158.16.1789</pub-id>
<?supplied-pmid 9738608?><pub-id pub-id-type="pmid">9738608</pub-id></mixed-citation>
              </ref>
              <ref id="pmed.1003966.ref034">
                <label>34</label>
                <mixed-citation publication-type="journal"><name><surname>Eisenmann</surname><given-names>J</given-names></name>, <name><surname>Milburn</surname><given-names>N</given-names></name>, <name><surname>Jacobsen</surname><given-names>L</given-names></name>, <name><surname>Moore</surname><given-names>S</given-names></name>. <article-title>Reliability and convergent validity of the Godin Leisure-Time Exercise Questionnaire in rural 5th-grade school-children.</article-title><source>J Hum Movement Stud</source>. <year>2002</year>;<volume>43</volume>(<issue>2</issue>):<fpage>135</fpage>–<lpage>49</lpage>.</mixed-citation>
              </ref>
              <ref id="pmed.1003966.ref035">
                <label>35</label>
                <mixed-citation publication-type="journal"><name><surname>Hughes</surname><given-names>JR</given-names></name>, <name><surname>Keely</surname><given-names>JP</given-names></name>, <name><surname>Niaura</surname><given-names>RS</given-names></name>, <name><surname>Ossip-Klein</surname><given-names>DJ</given-names></name>, <name><surname>Richmond</surname><given-names>RL</given-names></name>, <name><surname>Swan</surname><given-names>GE</given-names></name>. <article-title>Measures of abstinence in clinical trials: issues and recommendations</article-title>. <source>Nicotine Tob Res</source>. <year>2003</year>;<volume>5</volume>(<issue>1</issue>):<fpage>13</fpage>–<lpage>25</lpage>. <?supplied-pmid 12745503?><pub-id pub-id-type="pmid">12745503</pub-id></mixed-citation>
              </ref>
              <ref id="pmed.1003966.ref036">
                <label>36</label>
                <mixed-citation publication-type="journal"><name><surname>McCaffrey</surname><given-names>N</given-names></name>, <name><surname>Kaambwa</surname><given-names>B</given-names></name>, <name><surname>Currow</surname><given-names>DC</given-names></name>, <name><surname>Ratcliffe</surname><given-names>J</given-names></name>. <article-title>Health-related quality of life measured using the EQ-5D–5L: South Australian population norms.</article-title><source>Health Qual Life Outcomes</source>. <year>2016</year>;<volume>14</volume>(<issue>1</issue>):<fpage>133</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12955-016-0537-0</pub-id><?supplied-pmid 27644755?><pub-id pub-id-type="pmid">27644755</pub-id></mixed-citation>
              </ref>
              <ref id="pmed.1003966.ref037">
                <label>37</label>
                <mixed-citation publication-type="journal"><name><surname>De Wit</surname><given-names>L</given-names></name>, <name><surname>Theuns</surname><given-names>P</given-names></name>, <name><surname>Dejaeger</surname><given-names>E</given-names></name>, <name><surname>Devos</surname><given-names>S</given-names></name>, <name><surname>Gantenbein</surname><given-names>AR</given-names></name>, <name><surname>Kerckhofs</surname><given-names>E</given-names></name>, <etal>et al</etal>. <article-title>Long-term impact of stroke on patients’ health-related quality of life</article-title>. <source>Disabil Rehabil</source>. <year>2017</year>;<volume>39</volume>(<issue>14</issue>):<fpage>1435</fpage>–<lpage>40</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1080/09638288.2016.1200676</pub-id>
<?supplied-pmid 27385479?><pub-id pub-id-type="pmid">27385479</pub-id></mixed-citation>
              </ref>
              <ref id="pmed.1003966.ref038">
                <label>38</label>
                <mixed-citation publication-type="journal"><name><surname>Simon Pickard</surname><given-names>A</given-names></name>, <name><surname>Johnson</surname><given-names>JA</given-names></name>, <name><surname>Feeny</surname><given-names>DH</given-names></name>. <article-title>Responsiveness of generic health-related quality of life measures in stroke</article-title>. <source>Qual Life Res</source>. <year>2005</year>;<volume>14</volume>(<issue>1</issue>):<fpage>207</fpage>–<lpage>19</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s11136-004-3928-3</pub-id>
<?supplied-pmid 15789955?><pub-id pub-id-type="pmid">15789955</pub-id></mixed-citation>
              </ref>
              <ref id="pmed.1003966.ref039">
                <label>39</label>
                <mixed-citation publication-type="book"><collab>Australian Institute of Health and Welfare</collab>. <source>Insufficient physical activity. PHE 248.</source><publisher-loc>Canberra</publisher-loc>: <publisher-name>Australian Institute of Health and Welfare</publisher-name>; <year>2020</year> [cited 2021 Mar 22]. Available from: <ext-link xlink:href="https://www.aihw.gov.au/reports/risk-factors/insufficient-physical-activity/contents/insufficient-physical-activity" ext-link-type="uri">https://www.aihw.gov.au/reports/risk-factors/insufficient-physical-activity/contents/insufficient-physical-activity</ext-link>.</mixed-citation>
              </ref>
              <ref id="pmed.1003966.ref040">
                <label>40</label>
                <mixed-citation publication-type="journal"><name><surname>Slark</surname><given-names>J</given-names></name>, <name><surname>Bentley</surname><given-names>P</given-names></name>, <name><surname>Majeed</surname><given-names>A</given-names></name>, <name><surname>Sharma</surname><given-names>P</given-names></name>. <article-title>Awareness of stroke symptomatology and cardiovascular risk factors amongst stroke survivors</article-title>. <source>J Stroke Cerebrovasc Dis</source>. <year>2012</year>;<volume>21</volume>(<issue>5</issue>):<fpage>358</fpage>–<lpage>62</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jstrokecerebrovasdis.2010.09.010</pub-id>
<?supplied-pmid 21111631?><pub-id pub-id-type="pmid">21111631</pub-id></mixed-citation>
              </ref>
              <ref id="pmed.1003966.ref041">
                <label>41</label>
                <mixed-citation publication-type="journal"><name><surname>Martínez-González</surname><given-names>MA</given-names></name>, <name><surname>Salas-Salvadó</surname><given-names>J</given-names></name>, <name><surname>Estruch</surname><given-names>R</given-names></name>, <name><surname>Corella</surname><given-names>D</given-names></name>, <name><surname>Fitó</surname><given-names>M</given-names></name>, <name><surname>Ros</surname><given-names>E</given-names></name>. <article-title>Benefits of the Mediterranean diet: insights from the PREDIMED study.</article-title><source>Prog Cardiovasc Dis.</source><year>2015</year>;<volume>58</volume>(<issue>1</issue>):<fpage>50</fpage>–<lpage>60</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.pcad.2015.04.003</pub-id>
<?supplied-pmid 25940230?><pub-id pub-id-type="pmid">25940230</pub-id></mixed-citation>
              </ref>
              <ref id="pmed.1003966.ref042">
                <label>42</label>
                <mixed-citation publication-type="journal"><name><surname>Chikritzhs</surname><given-names>T</given-names></name>, <name><surname>Stockwell</surname><given-names>T</given-names></name>, <name><surname>Naimi</surname><given-names>T</given-names></name>, <name><surname>Andreasson</surname><given-names>S</given-names></name>, <name><surname>Dangardt</surname><given-names>F</given-names></name>, <name><surname>Liang</surname><given-names>W</given-names></name>. <article-title>Has the leaning tower of presumed health benefits from ‘moderate’ alcohol use finally collapsed?</article-title><source>Addiction</source>. <year>2015</year>;<volume>110</volume>(<issue>5</issue>):<fpage>726</fpage>–<lpage>7</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/add.12828</pub-id>
<?supplied-pmid 25613200?><pub-id pub-id-type="pmid">25613200</pub-id></mixed-citation>
              </ref>
              <ref id="pmed.1003966.ref043">
                <label>43</label>
                <mixed-citation publication-type="journal"><name><surname>Hackett</surname><given-names>ML</given-names></name>, <name><surname>Pickles</surname><given-names>K</given-names></name>. <article-title>Part I: frequency of depression after stroke: an updated systematic review and meta-analysis of observational studies.</article-title><source>Int J Stroke</source>. <year>2014</year>;<volume>9</volume>(<issue>8</issue>):<fpage>1017</fpage>–<lpage>25</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/ijs.12357</pub-id>
<?supplied-pmid 25117911?><pub-id pub-id-type="pmid">25117911</pub-id></mixed-citation>
              </ref>
              <ref id="pmed.1003966.ref044">
                <label>44</label>
                <mixed-citation publication-type="journal"><name><surname>Knapp</surname><given-names>P</given-names></name>, <name><surname>Dunn-Roberts</surname><given-names>A</given-names></name>, <name><surname>Sahib</surname><given-names>N</given-names></name>, <name><surname>Cook</surname><given-names>L</given-names></name>, <name><surname>Astin</surname><given-names>F</given-names></name>, <name><surname>Kontou</surname><given-names>E</given-names></name>, <etal>et al</etal>. <article-title>Frequency of anxiety after stroke: an updated systematic review and meta-analysis of observational studies</article-title>. <source>Int J Stroke</source>. <year>2020</year>;<volume>15</volume>(<issue>3</issue>):<fpage>244</fpage>–<lpage>55</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1177/1747493019896958</pub-id>
<?supplied-pmid 31980004?><pub-id pub-id-type="pmid">31980004</pub-id></mixed-citation>
              </ref>
              <ref id="pmed.1003966.ref045">
                <label>45</label>
                <mixed-citation publication-type="book"><collab>Australian Bureau of Statistics</collab>. <source>National survey of mental health and wellbeing: summary of results</source>. <publisher-loc>Canberra</publisher-loc>: <publisher-name>Australian Bureau of Statistics</publisher-name>; <year>2008</year> [cited 2021 Jun 17]. Available from: <ext-link xlink:href="https://www.abs.gov.au/statistics/health/mental-health/national-survey-mental-health-and-wellbeing-summary-results/latest-release" ext-link-type="uri">https://www.abs.gov.au/statistics/health/mental-health/national-survey-mental-health-and-wellbeing-summary-results/latest-release</ext-link>.</mixed-citation>
              </ref>
              <ref id="pmed.1003966.ref046">
                <label>46</label>
                <mixed-citation publication-type="journal"><name><surname>Göthe</surname><given-names>F</given-names></name>, <name><surname>Enache</surname><given-names>D</given-names></name>, <name><surname>Wahlund</surname><given-names>L</given-names></name>, <name><surname>Winblad</surname><given-names>B</given-names></name>, <name><surname>Crisby</surname><given-names>M</given-names></name>, <name><surname>Lökk</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Cerebrovascular diseases and depression: epidemiology, mechanisms and treatment.</article-title><source>Panminerva Med</source>. <year>2012</year>;<volume>54</volume>(<issue>3</issue>):<fpage>161</fpage>. <?supplied-pmid 22801433?><pub-id pub-id-type="pmid">22801433</pub-id></mixed-citation>
              </ref>
              <ref id="pmed.1003966.ref047">
                <label>47</label>
                <mixed-citation publication-type="journal"><name><surname>Towfighi</surname><given-names>A</given-names></name>, <name><surname>Ovbiagele</surname><given-names>B</given-names></name>, <name><surname>Husseini</surname><given-names>NE</given-names></name>, <name><surname>Hackett</surname><given-names>ML</given-names></name>, <name><surname>Jorge</surname><given-names>RE</given-names></name>, <name><surname>Kissela</surname><given-names>BM</given-names></name>, <etal>et al</etal>. <article-title>Poststroke depression: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association</article-title>. <source>Stroke</source>. <year>2017</year>;<volume>48</volume>(<issue>2</issue>):<fpage>e30</fpage>–<lpage>43</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1161/STR.0000000000000113</pub-id>
<?supplied-pmid 27932603?><pub-id pub-id-type="pmid">27932603</pub-id></mixed-citation>
              </ref>
              <ref id="pmed.1003966.ref048">
                <label>48</label>
                <mixed-citation publication-type="journal"><name><surname>Becker</surname><given-names>KJ</given-names></name>. <article-title>Inflammation and the silent sequelae of stroke</article-title>. <source>Neurotherapeutics</source>. <year>2016</year>;<volume>13</volume>(<issue>4</issue>):<fpage>801</fpage>–<lpage>10</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s13311-016-0451-5</pub-id>
<?supplied-pmid 27324389?><pub-id pub-id-type="pmid">27324389</pub-id></mixed-citation>
              </ref>
              <ref id="pmed.1003966.ref049">
                <label>49</label>
                <mixed-citation publication-type="book"><collab>Stroke Foundation</collab>. <source>EnableMe: helping with your own stroke recovery.</source><publisher-loc>Melbourne</publisher-loc>: <publisher-name>Stroke</publisher-name> Foundation; 2021 [cited 2021 Apr 1]. Available from: <ext-link xlink:href="https://enableme.org.au/" ext-link-type="uri">https://enableme.org.au/</ext-link>.</mixed-citation>
              </ref>
            </ref-list>
          </back>
          <sub-article article-type="editor-report" id="pmed.1003966.r001" specific-use="decision-letter">
            <front-stub>
              <article-id pub-id-type="doi">10.1371/journal.pmed.1003966.r001</article-id>
              <title-group>
                <article-title>Decision Letter 0</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Davidson</surname>
                    <given-names>Callam</given-names>
                  </name>
                  <role>Senior Editor</role>
                </contrib>
              </contrib-group>
              <permissions>
                <copyright-statement>© 2022 Callam Davidson</copyright-statement>
                <copyright-year>2022</copyright-year>
                <copyright-holder>Callam Davidson</copyright-holder>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
                </license>
              </permissions>
              <related-article ext-link-type="doi" xlink:href="10.1371/journal.pmed.1003966" id="rel-obj001" related-article-type="reviewed-article"/>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>Submission Version</meta-name>
                  <meta-value>0</meta-value>
                </custom-meta>
              </custom-meta-group>
            </front-stub>
            <body>
              <p>
                <named-content content-type="letter-date">19 Nov 2021</named-content>
              </p>
              <p>Dear Dr Guillaumier, </p>
              <p>Thank you for submitting your manuscript entitled "An online intervention for improving stroke survivors’ health related quality of life: a randomised controlled trial" for consideration by PLOS Medicine.</p>
              <p>Your manuscript has now been evaluated by the PLOS Medicine editorial staff and I am writing to let you know that we would like to send your submission out for external peer review.</p>
              <p>However, before we can send your manuscript to reviewers, we need you to complete your submission by providing the metadata that is required for full assessment. To this end, please login to Editorial Manager where you will find the paper in the 'Submissions Needing Revisions' folder on your homepage. Please click 'Revise Submission' from the Action Links and complete all additional questions in the submission questionnaire.</p>
              <p>Please re-submit your manuscript within two working days, i.e. by Nov 23 2021 11:59PM.</p>
              <p>Login to Editorial Manager here: <ext-link xlink:href="https://www.editorialmanager.com/pmedicine" ext-link-type="uri">https://www.editorialmanager.com/pmedicine</ext-link></p>
              <p>Once your full submission is complete, your paper will undergo a series of checks in preparation for peer review. Once your manuscript has passed all checks it will be sent out for review. </p>
              <p>Feel free to email us at <email>plosmedicine@plos.org</email> if you have any queries relating to your submission.</p>
              <p>Kind regards,</p>
              <p>Callam Davidson</p>
              <p>Associate Editor</p>
              <p>PLOS Medicine</p>
            </body>
          </sub-article>
          <sub-article article-type="aggregated-review-documents" id="pmed.1003966.r002" specific-use="decision-letter">
            <front-stub>
              <article-id pub-id-type="doi">10.1371/journal.pmed.1003966.r002</article-id>
              <title-group>
                <article-title>Decision Letter 1</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Davidson</surname>
                    <given-names>Callam</given-names>
                  </name>
                  <role>Senior Editor</role>
                </contrib>
              </contrib-group>
              <permissions>
                <copyright-statement>© 2022 Callam Davidson</copyright-statement>
                <copyright-year>2022</copyright-year>
                <copyright-holder>Callam Davidson</copyright-holder>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
                </license>
              </permissions>
              <related-article ext-link-type="doi" xlink:href="10.1371/journal.pmed.1003966" id="rel-obj002" related-article-type="reviewed-article"/>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>Submission Version</meta-name>
                  <meta-value>1</meta-value>
                </custom-meta>
              </custom-meta-group>
            </front-stub>
            <body>
              <p>
                <named-content content-type="letter-date">10 Jan 2022</named-content>
              </p>
              <p>Dear Dr. Guillaumier,</p>
              <p>Thank you very much for submitting your manuscript "An online intervention for improving stroke survivors’ health related quality of life: a randomised controlled trial" (PMEDICINE-D-21-04741R1) for consideration at PLOS Medicine. </p>
              <p>Your paper was evaluated by an associate editor and discussed among all the editors here. It was also discussed with an academic editor with relevant expertise, and sent to independent reviewers, including a statistical reviewer. The reviews are appended at the bottom of this email.</p>
              <p>In light of these reviews, I am afraid that we will not be able to accept the manuscript for publication in the journal in its current form, but we would like to consider a revised version that addresses the reviewers' and editors' comments. Obviously we cannot make any decision about publication until we have seen the revised manuscript and your response, and we plan to seek re-review by one or more of the reviewers. </p>
              <p>In revising the manuscript for further consideration, your revisions should address the specific points made by each reviewer and the editors. Please also check the guidelines for revised papers at <ext-link xlink:href="http://journals.plos.org/plosmedicine/s/revising-your-manuscript" ext-link-type="uri">http://journals.plos.org/plosmedicine/s/revising-your-manuscript</ext-link> for any that apply to your paper. In your rebuttal letter you should indicate your response to the reviewers' and editors' comments, the changes you have made in the manuscript, and include either an excerpt of the revised text or the location (eg: page and line number) where each change can be found. Please submit a clean version of the paper as the main article file; a version with changes marked should be uploaded as a marked up manuscript.</p>
              <p>In addition, we request that you upload any figures associated with your paper as individual TIF or EPS files with 300dpi resolution at resubmission; please read our figure guidelines for more information on our requirements: <ext-link xlink:href="http://journals.plos.org/plosmedicine/s/figures" ext-link-type="uri">http://journals.plos.org/plosmedicine/s/figures</ext-link>. While revising your submission, please upload your figure files to the PACE digital diagnostic tool, <ext-link xlink:href="https://pacev2.apexcovantage.com/" ext-link-type="uri">https://pacev2.apexcovantage.com/</ext-link>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <email>PLOSMedicine@plos.org</email>.</p>
              <p>We hope to receive your revised manuscript by Jan 31 2022 11:59PM. Please email us (<email>plosmedicine@plos.org</email>) if you have any questions or concerns.</p>
              <p>***Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.***</p>
              <p>We ask every co-author listed on the manuscript to fill in a contributing author statement, making sure to declare all competing interests. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. If new competing interests are declared later in the revision process, this may also hold up the submission. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT. You can see our competing interests policy here: <ext-link xlink:href="http://journals.plos.org/plosmedicine/s/competing-interests" ext-link-type="uri">http://journals.plos.org/plosmedicine/s/competing-interests</ext-link>.</p>
              <p>Please use the following link to submit the revised manuscript: </p>
              <p>
                <ext-link xlink:href="https://www.editorialmanager.com/pmedicine/" ext-link-type="uri">https://www.editorialmanager.com/pmedicine/</ext-link>
              </p>
              <p>Your article can be found in the "Submissions Needing Revision" folder. </p>
              <p>To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at <ext-link xlink:href="https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols" ext-link-type="uri">https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols</ext-link></p>
              <p>Please ensure that the paper adheres to the PLOS Data Availability Policy (see <ext-link xlink:href="http://journals.plos.org/plosmedicine/s/data-availability" ext-link-type="uri">http://journals.plos.org/plosmedicine/s/data-availability</ext-link>), which requires that all data underlying the study's findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by "data not shown" or "unpublished results." For such statements, authors must provide supporting data or cite public sources that include it. </p>
              <p>We look forward to receiving your revised manuscript. </p>
              <p>Sincerely,</p>
              <p>Callam Davidson, </p>
              <p>Associate Editor</p>
              <p>PLOS Medicine</p>
              <p>
                <ext-link xlink:href="http://plosmedicine.org" ext-link-type="uri">plosmedicine.org</ext-link>
              </p>
              <p>-----------------------------------------------------------</p>
              <p>Requests from the editors:</p>
              <p>Abstract</p>
              <p>Please report your abstract according to CONSORT for abstracts, following the PLOS Medicine abstract structure (Background, Methods and Findings, Conclusions) <ext-link xlink:href="http://www.consort-statement.org/extensions?ContentWidgetId=562" ext-link-type="uri">http://www.consort-statement.org/extensions?ContentWidgetId=562</ext-link></p>
              <p>Abstract Methods and Findings:</p>
              <p>* Please include the population and setting and provide a summary of the population demographics.</p>
              <p>* Please specify who was blinded to the intervention and control.</p>
              <p>* Please state that analysis was intention to treat (in both the abstract and the methods).</p>
              <p>* Please provide the number of participants and the number of participants lost to follow up in each group.</p>
              <p>* Please include relevant p values when quantifying your results.</p>
              <p>* Please include the important dependent variables that are adjusted for in the analyses.</p>
              <p>* In the last sentence of the Abstract Methods and Findings section, please describe the main limitation(s) of the study's methodology.</p>
              <p>In the Abstract Conclusions, please interpret the study based on the results presented in the abstract, emphasizing what is new without overstating your conclusions.</p>
              <p>General</p>
              <p>Please remove the table of abbreviations and instead define abbreviations on first use.</p>
              <p>At this stage, we ask that you include a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract. Please see our author guidelines for more information: <ext-link xlink:href="https://journals.plos.org/plosmedicine/s/revising-your-manuscript#loc-author-summary" ext-link-type="uri">https://journals.plos.org/plosmedicine/s/revising-your-manuscript#loc-author-summary</ext-link></p>
              <p>Citations should be in square brackets, and preceding punctuation.</p>
              <p>Methods and Results</p>
              <p>Thank you for completing the CONSORT checklist - please update to use section and paragraph numbers, rather than page numbers (as these are likely to change during the revision process). </p>
              <p>Please define the abbreviations in Figure 1.</p>
              <p>Please define "lost to follow-up" as used in this study. Other reasons for exclusion should be defined.</p>
              <p>The protocol states that the research team ‘will monitor the ethics and safety of the trial’ – please confirm whether any relevant safety events were reported.</p>
              <p>Please provide the actual numbers of events for the outcomes, not just summary statistics or ORs.</p>
              <p>Please define the abbreviations in Table 3.</p>
              <p>Other</p>
              <p>All content on page 16 (author contributions, funding, and disclosures) can be removed as this information will be captured as metadata based on your responses to the submission form.</p>
              <p>Please only use et al. after listing the first six authors in your references and use the journal name abbreviations found in the National Center for Biotechnology Information (NCBI) databases. See here for further information: <ext-link xlink:href="https://journals.plos.org/plosmedicine/s/submission-guidelines#loc-references" ext-link-type="uri">https://journals.plos.org/plosmedicine/s/submission-guidelines#loc-references</ext-link>
</p>
              <p>Comments from the reviewers:</p>
              <p>Reviewer #1: Statistical review</p>
              <p>This paper reports a randomised controlled trial comparing an online intervention for stroke survivors. The authors demonstrate that this provides significant better primary outcome compared to a control group. </p>
              <p>I had some comments on the paper, split into major and minor:</p>
              <p>Major comments</p>
              <p>1. Outcomes, page 8: I found it a bit confusing about what the primary outcome was - the EQ VAS is mentioned in the protocol paper although not clearly as the primary outcome; it's not mentioned in the ANZCTR (just EQ-5D-5L). I'm not an expert in the EQ-5D measurement which might explain my confusion, but I would welcome clarification on whether the specific primary outcome used in this paper was unambiguously pre-defined. This is especially true as EQ VAS results are significant but EQ-5D-5L results are not (although not far off).</p>
              <p>2. Statistical analysis/Results: I note there was quite strong difference in missing data rates between arms. Since it's possible that the missing data may be missing not at random (it is plausible that individuals with worse outcomes were more likely to be lost to follow-up), are the authors concerned that this may explain the significant difference in results? This is especially true as the intervention did not significantly improve the behaviours that would be the mechanism to improving QoL. It may be useful to demonstrate that a large difference in missing outcomes (compared to computed outcomes assuming MAR) would be required to explain the significant results (a tipping point sensitivity analysis</p>
              <p>Minor comments</p>
              <p>3. Abstract: It is not clear if the reported median and 95% CI is the improvement in the intervention group or the difference between arms. I note later that it is the difference - I would recommend making this clearer. Please add the p-value for significance.</p>
              <p>4. Abstract: Assuming the secondary outcomes listed are all of the secondary outcomes, I'd recommend changing 'included' to 'were'. </p>
              <p>5. Abstract: As this was a prospectively powered trial it is appropriate to provide p-values in addition to the confidence intervals.</p>
              <p>6. Statistical analysis, page 9: I understand the reason for using quantile regression instead of the analysis specified in the protocol, but I would recommend that it is highlighted as a difference to the protocol.</p>
              <p>7. Page 11 - as per comment 3, please make clearer this is the between group difference and add the p-value.</p>
              <p>James Wason</p>
              <p>Reviewer #2: </p>
              <p>Important and often understudied work on improving HRQoL using an online behavioral intervention in stroke survivors.</p>
              <p>Incomplete information provided for funders (e.g., websites). In the abstract and introduction, it would help to define or make clear the difference between the primary and secondary HRQoL outcomes. Methods: How was “sufficient facility in Internet use” determined? The inclusion criteria state acute stroke or TIA while randomization was stratified by type of stroke defined as stroke TIA or other. Please clarify what is meant by “other.” Please clarify what additional “prompts” were used in the intervention group and frequency. Was “time since stroke” considered during data analysis? Were data collected on intervention usability (e.g., number of times accessed the intervention and what resources or modules were accessed, perhaps some more than others)? Discussion: Any differences noted between those that completed the study and those that were lost to follow-up? Perhaps higher rates of depression and anxiety in those lost to follow-up which was significant in the intervention arm. Same question of the 20% in the intervention arm that did not access or engage in the online program during the intervention time frame. Would also help to understand the reasons why these individuals did not access the program (e.g., technical difficulties etc.). </p>
              <p>Reviewer #3: Abstract</p>
              <p>First sentence implies this is a study about secondary prevention-which is not consistent with the second sentence about quality of life. </p>
              <p>Surveys are mentioned in the abstract-presumably these were the outcome questionnaires? If so can they clarify this please?</p>
              <p>Primary outcome-should this be the 'change in VAS between baseline and 6 months' rather than the VAS? </p>
              <p>Main paper</p>
              <p>The rationale for an intervention preventing stroke recurrence having an effect on quality of life (as the primary outcome) needs to be made more clearly.</p>
              <p>What was the rationale providing a list of internet links in the control group-was this an 'active control' or 'usual care'. </p>
              <p>Power calculations: 6 point difference in EQ-VAS: why was this chosen and is it of any clinical relevance? </p>
              <p>10.8% were lost to follow-up. The authors could describe how they attempted to minimise loss to follow-up, as this level of loss has the potential to introduce bias into the results. </p>
              <p>Physical activity was measured by self-report-to what extent was this valid? Did the authors consider directly measured activity, and if so, why was self-report chosen?</p>
              <p>Fatigue affects around 50% of stroke survivors and can have a major impact on quality of life. Why was fatigue not measured as an outcome? Is it plausible that an on-line programme like this could influence fatigue through a range of different mechanisms, and this might improve HRQUOL?</p>
            </body>
          </sub-article>
          <sub-article article-type="author-comment" id="pmed.1003966.r003">
            <front-stub>
              <article-id pub-id-type="doi">10.1371/journal.pmed.1003966.r003</article-id>
              <title-group>
                <article-title>Author response to Decision Letter 1</article-title>
              </title-group>
              <related-article ext-link-type="doi" xlink:href="10.1371/journal.pmed.1003966" id="rel-obj003" related-article-type="editor-report"/>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>Submission Version</meta-name>
                  <meta-value>2</meta-value>
                </custom-meta>
              </custom-meta-group>
            </front-stub>
            <body>
              <p>
                <named-content content-type="author-response-date">28 Feb 2022</named-content>
              </p>
              <supplementary-material id="pmed.1003966.s003" position="float" content-type="local-data">
                <label>Attachment</label>
                <caption>
                  <p>Submitted filename: <named-content content-type="submitted-filename">PLOSMed Response Letter_240122.docx</named-content></p>
                </caption>
                <media xlink:href="pmed.1003966.s003.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </body>
          </sub-article>
          <sub-article article-type="aggregated-review-documents" id="pmed.1003966.r004" specific-use="decision-letter">
            <front-stub>
              <article-id pub-id-type="doi">10.1371/journal.pmed.1003966.r004</article-id>
              <title-group>
                <article-title>Decision Letter 2</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Davidson</surname>
                    <given-names>Callam</given-names>
                  </name>
                  <role>Senior Editor</role>
                </contrib>
              </contrib-group>
              <permissions>
                <copyright-statement>© 2022 Callam Davidson</copyright-statement>
                <copyright-year>2022</copyright-year>
                <copyright-holder>Callam Davidson</copyright-holder>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
                </license>
              </permissions>
              <related-article ext-link-type="doi" xlink:href="10.1371/journal.pmed.1003966" id="rel-obj004" related-article-type="reviewed-article"/>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>Submission Version</meta-name>
                  <meta-value>2</meta-value>
                </custom-meta>
              </custom-meta-group>
            </front-stub>
            <body>
              <p>
                <named-content content-type="letter-date">14 Mar 2022</named-content>
              </p>
              <p>Dear Dr. Guillaumier,</p>
              <p>Thank you very much for re-submitting your manuscript "An online intervention for improving stroke survivors’ health related quality of life: a randomised controlled trial" (PMEDICINE-D-21-04741R2) for review by PLOS Medicine.</p>
              <p>I have discussed the paper with my colleagues and the academic editor and it was also seen again by one reviewer. I am pleased to say that provided the remaining editorial and production issues are dealt with we are planning to accept the paper for publication in the journal.</p>
              <p>The remaining issues that need to be addressed are listed at the end of this email. Any accompanying reviewer attachments can be seen via the link below. Please take these into account before resubmitting your manuscript:</p>
              <p>[LINK]</p>
              <p>***Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.***</p>
              <p>In revising the manuscript for further consideration here, please ensure you address the specific points made by each reviewer and the editors. In your rebuttal letter you should indicate your response to the reviewers' and editors' comments and the changes you have made in the manuscript. Please submit a clean version of the paper as the main article file. A version with changes marked must also be uploaded as a marked up manuscript file.</p>
              <p>Please also check the guidelines for revised papers at <ext-link xlink:href="http://journals.plos.org/plosmedicine/s/revising-your-manuscript" ext-link-type="uri">http://journals.plos.org/plosmedicine/s/revising-your-manuscript</ext-link> for any that apply to your paper. If you haven't already, we ask that you provide a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract.</p>
              <p>We hope to receive your revised manuscript within 1 week. Please email us (<email>plosmedicine@plos.org</email>) if you have any questions or concerns.</p>
              <p>We ask every co-author listed on the manuscript to fill in a contributing author statement. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT.</p>
              <p>Please ensure that the paper adheres to the PLOS Data Availability Policy (see <ext-link xlink:href="http://journals.plos.org/plosmedicine/s/data-availability" ext-link-type="uri">http://journals.plos.org/plosmedicine/s/data-availability</ext-link>), which requires that all data underlying the study's findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by "data not shown" or "unpublished results." For such statements, authors must provide supporting data or cite public sources that include it.</p>
              <p>To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at <ext-link xlink:href="https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols" ext-link-type="uri">https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols</ext-link></p>
              <p>Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript.</p>
              <p>Please note, when your manuscript is accepted, an uncorrected proof of your manuscript will be published online ahead of the final version, unless you've already opted out via the online submission form. If, for any reason, you do not want an earlier version of your manuscript published online or are unsure if you have already indicated as such, please let the journal staff know immediately at <email>plosmedicine@plos.org</email>.</p>
              <p>If you have any questions in the meantime, please contact me or the journal staff on <email>plosmedicine@plos.org</email>.  </p>
              <p>We look forward to receiving the revised manuscript by Mar 21 2022 11:59PM.   </p>
              <p>Sincerely,</p>
              <p>Callam Davidson, </p>
              <p>Associate Editor </p>
              <p>PLOS Medicine</p>
              <p>
                <ext-link xlink:href="http://plosmedicine.org" ext-link-type="uri">plosmedicine.org</ext-link>
              </p>
              <p>------------------------------------------------------------</p>
              <p>Requests from Editors:</p>
              <p>Please update your title to “Evaluation of an online intervention for improving stroke survivors’ health related quality of life: a randomised controlled trial”.</p>
              <p>Please cite your CONSORT checklist in the Methods, with a statement similar to ‘We reported our trial according to the Consolidated Standards of Reporting Trials (CONSORT) guidelines (S1 CONSORT Checklist)’.</p>
              <p>The term gender is used in Table 1 and Supplementary Table 1. Please consult <ext-link xlink:href="http://www.who.int/gender/whatisgender/en/" ext-link-type="uri">http://www.who.int/gender/whatisgender/en/</ext-link> and confirm that gender is correct term in this context (or whether sex would be more appropriate).</p>
              <p>In the references, Journal name abbreviations should be those found in the National Center for Biotechnology Information (NCBI) databases. </p>
              <p>References 5, 11, and 40-42: Please update the DOI to remove <ext-link xlink:href="https://doi.org/" ext-link-type="uri">https://doi.org/</ext-link> (such that the format is consistent with e.g. reference 8).</p>
              <p>Please add the date of citation to reference 49. </p>
              <p>Comments from Reviewers:</p>
              <p>Reviewer #1: Thank you to the authors for revising their paper on the basis of my previous comments. My major concerns have been addressed well and I have no further issues to raise.</p>
              <p>Any attachments provided with reviews can be seen via the following link:</p>
              <p>[LINK]</p>
            </body>
          </sub-article>
          <sub-article article-type="author-comment" id="pmed.1003966.r005">
            <front-stub>
              <article-id pub-id-type="doi">10.1371/journal.pmed.1003966.r005</article-id>
              <title-group>
                <article-title>Author response to Decision Letter 2</article-title>
              </title-group>
              <related-article ext-link-type="doi" xlink:href="10.1371/journal.pmed.1003966" id="rel-obj005" related-article-type="editor-report"/>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>Submission Version</meta-name>
                  <meta-value>3</meta-value>
                </custom-meta>
              </custom-meta-group>
            </front-stub>
            <body>
              <p>
                <named-content content-type="author-response-date">15 Mar 2022</named-content>
              </p>
              <supplementary-material id="pmed.1003966.s004" position="float" content-type="local-data">
                <label>Attachment</label>
                <caption>
                  <p>Submitted filename: <named-content content-type="submitted-filename">PLOSMed Response Letter_R2_160322.docx</named-content></p>
                </caption>
                <media xlink:href="pmed.1003966.s004.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </body>
          </sub-article>
          <sub-article article-type="editor-report" id="pmed.1003966.r006" specific-use="decision-letter">
            <front-stub>
              <article-id pub-id-type="doi">10.1371/journal.pmed.1003966.r006</article-id>
              <title-group>
                <article-title>Decision Letter 3</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Davidson</surname>
                    <given-names>Callam</given-names>
                  </name>
                  <role>Senior Editor</role>
                </contrib>
              </contrib-group>
              <permissions>
                <copyright-statement>© 2022 Callam Davidson</copyright-statement>
                <copyright-year>2022</copyright-year>
                <copyright-holder>Callam Davidson</copyright-holder>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
                </license>
              </permissions>
              <related-article ext-link-type="doi" xlink:href="10.1371/journal.pmed.1003966" id="rel-obj006" related-article-type="reviewed-article"/>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>Submission Version</meta-name>
                  <meta-value>3</meta-value>
                </custom-meta>
              </custom-meta-group>
            </front-stub>
            <body>
              <p>
                <named-content content-type="letter-date">16 Mar 2022</named-content>
              </p>
              <p>Dear Dr Guillaumier, </p>
              <p>On behalf of my colleagues and the Academic Editor, Dr Joshua Willey, I am pleased to inform you that we have agreed to publish your manuscript "Evaluation of an online intervention for improving stroke survivors’ health related quality of life: a randomised controlled trial" (PMEDICINE-D-21-04741R3) in PLOS Medicine.</p>
              <p>Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. Please be aware that it may take several days for you to receive this email; during this time no action is required by you. Once you have received these formatting requests, please note that your manuscript will not be scheduled for publication until you have made the required changes.</p>
              <p>In the meantime, please log into Editorial Manager at <ext-link xlink:href="http://www.editorialmanager.com/pmedicine/" ext-link-type="uri">http://www.editorialmanager.com/pmedicine/</ext-link>, click the "Update My Information" link at the top of the page, and update your user information to ensure an efficient production process. </p>
              <p>PRESS</p>
              <p>We frequently collaborate with press offices. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximise its impact. If the press office is planning to promote your findings, we would be grateful if they could coordinate with <email>medicinepress@plos.org</email>. If you have not yet opted out of the early version process, we ask that you notify us immediately of any press plans so that we may do so on your behalf.</p>
              <p>We also ask that you take this opportunity to read our Embargo Policy regarding the discussion, promotion and media coverage of work that is yet to be published by PLOS. As your manuscript is not yet published, it is bound by the conditions of our Embargo Policy. Please be aware that this policy is in place both to ensure that any press coverage of your article is fully substantiated and to provide a direct link between such coverage and the published work. For full details of our Embargo Policy, please visit <ext-link xlink:href="http://www.plos.org/about/media-inquiries/embargo-policy/" ext-link-type="uri">http://www.plos.org/about/media-inquiries/embargo-policy/</ext-link>.</p>
              <p>To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at <ext-link xlink:href="https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols" ext-link-type="uri">https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols</ext-link></p>
              <p>Thank you again for submitting to PLOS Medicine. We look forward to publishing your paper. </p>
              <p>Sincerely, </p>
              <p>Callam Davidson </p>
              <p>Associate Editor </p>
              <p>PLOS Medicine</p>
            </body>
          </sub-article>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
